BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 782] [Article Influence: 156.2] [Reference Citation Analysis]
Number Citing Articles
1 Alnuqaydan AM, Rah B. Tamarix articulata Inhibits Cell Proliferation, Promotes Cell Death Mechanisms and Triggers G0/G1 Cell Cycle Arrest in Hepatocellular Carcinoma Cells. Food Technol Biotechnol 2021;59:162-73. [PMID: 34316277 DOI: 10.17113/ftb.59.02.21.6904] [Reference Citation Analysis]
2 Hao XY, Li AQ, Shi H, Guo TK, Shen YF, Deng Y, Wang LT, Wang T, Cai H. A novel DNA methylation-based model that effectively predicts prognosis in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203945. [PMID: 33634306 DOI: 10.1042/BSR20203945] [Reference Citation Analysis]
3 Taylor EJ, Rowe IA. Surveillance for Hepatocellular Carcinoma. In: Cross T, Palmer DH, editors. Liver Cancers. Cham: Springer International Publishing; 2019. pp. 13-21. [DOI: 10.1007/978-3-319-92216-4_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Zhang F, Lu C, Zhang X, Chen Z, Zhong C, Hu Y, Wei X, Zhou B, Wang K, Chai Z, Wu M, Lau WY, Cheng S. The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. HPB 2020;22:1025-33. [DOI: 10.1016/j.hpb.2019.10.2439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, Xiao B, Hu Y, Qian Y, Cai T, Fu L. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal 2020;34:e23200. [PMID: 31916309 DOI: 10.1002/jcla.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhao E, Chen S, Dang Y. Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:620765. [PMID: 33553243 DOI: 10.3389/fmolb.2020.620765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xu H, Chen K, Shang R, Chen X, Zhang Y, Song X, Evert M, Zhong S, Li B, Calvisi DF, Chen X. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death Dis 2021;12:920. [PMID: 34625531 DOI: 10.1038/s41419-021-04206-5] [Reference Citation Analysis]
8 de Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, Tselikas L, Dioguardi Burgio M, Raynaud L, Deschamps F, Verset G. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers (Basel) 2020;12:E3405. [PMID: 33212917 DOI: 10.3390/cancers12113405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Glassberg MB, Ghosh S, Clymer JW, Qadeer RA, Ferko NC, Sadeghirad B, Wright GW, Amaral JF. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther 2019;12:6407-38. [PMID: 31496742 DOI: 10.2147/OTT.S204340] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
10 Chen W, Zhang Z, Fang X, Xiong L, Wen Y, Zhou J, Kong F, Zou H. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion. Medicine (Baltimore) 2021;100:e26265. [PMID: 34128857 DOI: 10.1097/MD.0000000000026265] [Reference Citation Analysis]
11 Li Z, Tian Y, Qu L, Mao J, Zhong H. AAV-Mig-6 Increase the Efficacy of TAE in VX2 Rabbit Model, Is Associated With JNK Mediated Autophagy. J Cancer 2019;10:1060-9. [PMID: 30854112 DOI: 10.7150/jca.27418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ferreira-Silva GÁ, Lages CCL, Sartorelli P, Hasegawa FR, Soares MG, Ionta M. Casearin D inhibits ERK phosphorylation and induces downregulation of cyclin D1 in HepG2 cells. Toxicol In Vitro 2017;38:27-32. [PMID: 27806920 DOI: 10.1016/j.tiv.2016.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Wang H, Li L, Bo W, Liu A, Feng X, Hu Y, Tian L, Zhang H, Tang X, Zhang L, Zhang M. Immediate postoperative Fibrosis-4 predicts postoperative liver failure for patients with hepatocellular carcinoma undergoing curative surgery. Digestive and Liver Disease 2018;50:61-7. [DOI: 10.1016/j.dld.2017.09.127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Nault J, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie‐bergman C, Ziol M, Bioulac‐sage P, Couchy G, Blanc J, Nahon P, Amaddeo G, Ganne‐carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman‐rossi J. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology 2020;71:164-82. [DOI: 10.1002/hep.30811] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 47.0] [Reference Citation Analysis]
15 Chen L, Cai BB, Zhou CJ, Hou XQ, Hu SP, Fang G, Chen WC, Li LH, Yang WJ. A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma. Cancer Manag Res 2019;11:693-703. [PMID: 30679923 DOI: 10.2147/CMAR.S193593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Shang X, Li G, Liu H, Li T, Liu J, Zhao Q, Wang C. Comprehensive Circular RNA Profiling Reveals That hsa_circ_0005075, a New Circular RNA Biomarker, Is Involved in Hepatocellular Crcinoma Development. Medicine (Baltimore). 2016;95:e3811. [PMID: 27258521 DOI: 10.1097/md.0000000000003811] [Cited by in Crossref: 216] [Cited by in F6Publishing: 160] [Article Influence: 54.0] [Reference Citation Analysis]
17 Schellhaas B, Strobel D, Stumpf M, Ganslmayer M, Pfeifer L, Goertz RS, Neurath MF, Zopf S. Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts. European Journal of Gastroenterology & Hepatology 2018;30:1422-7. [DOI: 10.1097/meg.0000000000001221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Zeng JY, Piao XH, Zou ZY, Yang QF, Qin ZL, Chen JB, Zhou L, Niu LZ, Liu JG. Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis. Oncotarget 2018;9:7557-66. [PMID: 29484132 DOI: 10.18632/oncotarget.24029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK, Kuznetsov VA. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol 2018;12:89-113. [PMID: 29117471 DOI: 10.1002/1878-0261.12153] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
20 Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. J Gastrointest Surg 2021. [PMID: 34345997 DOI: 10.1007/s11605-021-05095-x] [Reference Citation Analysis]
21 Zheng Y, Nie P, Xu S. Long noncoding RNA linc00467 plays an oncogenic role in hepatocellular carcinoma by regulating the miR-18a-5p/NEDD9 axis. J Cell Biochem 2020;121:3135-44. [PMID: 31916278 DOI: 10.1002/jcb.29581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials. PLoS One 2020;15:e0229492. [PMID: 32134981 DOI: 10.1371/journal.pone.0229492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Guan T, Shang W, Li H, Yang X, Fang C, Tian J, Wang K. From Detection to Resection: Photoacoustic Tomography and Surgery Guidance with Indocyanine Green Loaded Gold Nanorod@liposome Core-Shell Nanoparticles in Liver Cancer. Bioconjug Chem 2017;28:1221-8. [PMID: 28345887 DOI: 10.1021/acs.bioconjchem.7b00065] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
24 Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q, Lai J, Chen M, Zhao M. Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients? J Hepatocell Carcinoma 2020;7:377-84. [PMID: 33365285 DOI: 10.2147/JHC.S287641] [Reference Citation Analysis]
25 Qin F, Zhang J, Gong J, Zhang W. Identification and Validation of a Prognostic Model Based on Three Autophagy-Related Genes in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:5564040. [PMID: 33778066 DOI: 10.1155/2021/5564040] [Reference Citation Analysis]
26 Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol 2021:S1044-579X(21)00050-X. [PMID: 33647386 DOI: 10.1016/j.semcancer.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Bredt LC, Peres LAB. Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. Artif Intell Cancer 2021; 2(5): 51-59 [DOI: 10.35713/aic.v2.i5.51] [Reference Citation Analysis]
28 Huang WT, Chen ZX, He RQ, Wu YZ, Yin SY, Liang XN, Chen G, Yang H, Peng ZG, Yang LH. Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis. Onco Targets Ther 2016;9:5061-71. [PMID: 27574447 DOI: 10.2147/OTT.S111431] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2019;16:1541-8. [PMID: 31839741 DOI: 10.7150/ijms.37427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
30 Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 2018;12:99-107. [PMID: 29124987 DOI: 10.1080/17474124.2018.1403898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018; 24(32): 3626-3636 [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
32 Lai MW, Chu YD, Lin CL, Chien RN, Yeh TS, Pan TL, Ke PY, Lin KH, Yeh CT. Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? BMC Cancer 2019;19:250. [PMID: 30894157 DOI: 10.1186/s12885-019-5453-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019; 25(32): 4614-4628 [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
34 Freitas LBR, Longo L, Santos D, Grivicich I, Álvares-da-Silva MR. Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population. World J Hepatol 2019; 11(9): 678-688 [PMID: 31602288 DOI: 10.4254/wjh.v11.i9.678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif 2019;52:e12538. [PMID: 30341783 DOI: 10.1111/cpr.12538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
36 Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. J Cancer 2019;10:1189-96. [PMID: 30854128 DOI: 10.7150/jca.28994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
37 Sun B, Zhang J, Liu M, Guan L. Alkannin inhibits proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of miR-92a. Biomed Pharmacother 2019;114:108782. [PMID: 30909147 DOI: 10.1016/j.biopha.2019.108782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
38 Mu L, Sun L, Pan T, Lyu N, Li S, Li X, Wang J, Xie Q, Deng H, Zheng L, Peng J, Shen L, Fan W, Wu P, Zhao M. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. 2018;34:59-67. [PMID: 28540809 DOI: 10.1080/02656736.2017.1318332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zhong C, Zhang YF, Huang JH, Xiong CM, Wang ZY, Chen QL, Guo RP. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. BMC Cancer 2018;18:643. [PMID: 29879928 DOI: 10.1186/s12885-018-4557-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Manicardi N, Fernández-Iglesias A, Abad-Jordà L, Royo F, Azkargorta M, Ortega-Ribera M, Sanfeliu-Redondo D, Martínez-Alcocer A, Elortza F, Hessheimer AJ, Fondevila C, Lozano JJ, García-Pagán JC, Bosch J, Cubero FJ, Albillos A, Vaquero J, Falcón-Pérez JM, Gracia-Sancho J. Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers (Basel) 2021;13:2688. [PMID: 34072510 DOI: 10.3390/cancers13112688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Scott RA, Aithal GP, Francis ST, Irving WL. Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. Gastroenterology 2018;154:1848-50. [DOI: 10.1053/j.gastro.2017.12.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Xu Q, Yan Y, Gu S, Mao K, Zhang J, Huang P, Zhou Z, Chen Z, Zheng S, Liang J, Lin Z, Wang J, Yan J, Xiao Z. A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma. J Immunol Res. 2018;2018:4925498. [PMID: 30027102 DOI: 10.1155/2018/4925498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
43 Casals G, Perramón M, Casals E, Portolés I, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W. Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants (Basel) 2021;10:660. [PMID: 33923136 DOI: 10.3390/antiox10050660] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, Ferko N, Amaral JF. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. World J Surg Oncol 2019;17:98. [PMID: 31182102 DOI: 10.1186/s12957-019-1632-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
45 Aravinthan AD, Bruni SG, Doyle AC, Thein HH, Goldaracena N, Issachar A, Lilly LB, Selzner N, Bhat M, Sreeharsha B, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Greig PD, Renner EL, Grant DR, Sapisochin G. Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:1843-51. [PMID: 28160137 DOI: 10.1245/s10434-017-5789-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
46 Wu H, Xing H, Liang L, Huang B, Li C, Lau WY, Zhou Y, Gu W, Wang H, Chen T, Zhang Y, Zeng Y, Pawlik TM, Wang M, Wu M, Shen F, Yang T. Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. European Journal of Surgical Oncology 2019;45:2360-8. [DOI: 10.1016/j.ejso.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Chen S, Xu XL, Zhou B, Tian J, Luo BM, Zhang LM. Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. ACS Appl Mater Interfaces 2019;11:22194-205. [PMID: 31199110 DOI: 10.1021/acsami.9b06745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
48 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 7.7] [Reference Citation Analysis]
49 Zhang Y, Zhang M, Chen M, Mei J, Xu L, Guo R, Lin X, Li J, Peng Z. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2018;1:e183213. [PMID: 30646226 DOI: 10.1001/jamanetworkopen.2018.3213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
50 Zhang K, Che S, Su Z, Zheng S, Zhang H, Yang S, Li W, Liu J. CD90 promotes cell migration, viability and sphere‑forming ability of hepatocellular carcinoma cells. Int J Mol Med 2018;41:946-54. [PMID: 29251325 DOI: 10.3892/ijmm.2017.3314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
52 Zheng G, Mo F, Ling C, Peng H, Gu W, Li M, Chen Z. Portulaca oleracea L. alleviates liver injury in streptozotocin-induced diabetic mice. Drug Des Devel Ther 2018;12:47-55. [PMID: 29343942 DOI: 10.2147/DDDT.S121084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
53 Ho SY, Liu PH, Hsu CY, Chiou YY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Sci Rep. 2018;8:843. [PMID: 29339752 DOI: 10.1038/s41598-018-19251-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
54 Wang P, Yan Y, Yu W, Zhang H. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.Cell Prolif. 2019;52:e12626. [PMID: 31033072 DOI: 10.1111/cpr.12626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
55 Xie Q, Chen Z, Xia L, Zhao Q, Yu H, Yang Z. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population. Gene. 2018;674:188-194. [PMID: 29940275 DOI: 10.1016/j.gene.2018.06.069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
56 Chen Y, Zhao C, Yang Y, Xin YJ, Wang YN, Li X, Zhou X, Feng DP. Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. Cardiovasc Intervent Radiol 2020;43:1294-304. [PMID: 32435833 DOI: 10.1007/s00270-020-02519-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
57 Nault J, Sutter O, Nahon P, Ganne-carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology 2018;68:783-97. [DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 33.0] [Reference Citation Analysis]
58 Wang D, Wu Q, Guo R, Lu C, Niu M, Rao W. Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. Nanoscale 2021;13:8817-36. [PMID: 33960346 DOI: 10.1039/d1nr01268a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Schaap FG, Jansen PLM, Olde Damink SWM. Chronic elevation of plasma fibroblast growth factor 19 in long-term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern? Hepatology 2018;67:782-4. [PMID: 28865148 DOI: 10.1002/hep.29511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Chesnokov MS, Khesina PA, Shavochkina DA, Kustova IF, Dyakov LM, Morozova OV, Mugue NS, Kudashkin NE, Moroz EA, Patyutko YI, Lazarevich NL. Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. PeerJ 2018;6:e4915. [PMID: 29888133 DOI: 10.7717/peerj.4915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 González R, Rodríguez-Hernández MA, Negrete M, Ranguelova K, Rossin A, Choya-Foces C, Cruz-Ojeda P, Miranda-Vizuete A, Martínez-Ruiz A, Rius-Pérez S, Sastre J, Bárcena JA, Hueber AO, Padilla CA, Muntané J. Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biol 2020;34:101528. [PMID: 32388267 DOI: 10.1016/j.redox.2020.101528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
62 Wang D, Zhang S, Zhang T, Wan G, Chen B, Xiong Q, Zhang J, Zhang W, Wang Y. Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy. Int J Nanomedicine 2017;12:8649-70. [PMID: 29255359 DOI: 10.2147/IJN.S147591] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 5.8] [Reference Citation Analysis]
63 Dai T, Deng M, Ye L, Liu R, Lin G, Chen X, Li H, Liu W, Yang Y, Chen G, Wang G. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy.Am J Transl Res. 2020;12:2984-2997. [PMID: 32655824 DOI: NOT.DOI.32655824] [Reference Citation Analysis]
64 Wu M, Jiang L. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 33495920 DOI: 10.1007/s10620-021-06832-7] [Reference Citation Analysis]
65 Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med 2020;2:337-42. [PMID: 33330829 DOI: 10.35772/ghm.2020.01059] [Reference Citation Analysis]
66 Chen Y, Zhao H, Li H, Feng X, Tang H, Qiu C, Zhang J, Fu B. LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells. Mol Ther Nucleic Acids. 2020;19:168-178. [PMID: 31838274 DOI: 10.1016/j.omtn.2019.10.035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
67 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ho SY, Yuan MH, Chen CC, Liu PH, Hsu CY, Huang YH, Lei HJ, Lee RC, Huo TI. Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Dig Dis Sci 2020;65:3389-402. [PMID: 31955286 DOI: 10.1007/s10620-020-06053-4] [Reference Citation Analysis]
69 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
70 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 25.0] [Reference Citation Analysis]
71 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
72 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
73 Ye L, Kriegl L, Reiter FP, Munker SM, Itzel T, Teufel A, Ziesch A, Török HP, Kirchner T, Gerbes AL, Guba M, Mayerle J, De Toni EN. Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00124. [PMID: 31990698 DOI: 10.14309/ctg.0000000000000124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Cui Z, Li Y, Gao Y, Kong L, Lin Y, Chen Y. Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction. Aging (Albany NY) 2020;12:19455-67. [PMID: 33035196 DOI: 10.18632/aging.103879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Liu L, Wang E, Li L, Chen D, Peng K, Wang M, Han G. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Can J Gastroenterol Hepatol 2019;2019:2576349. [PMID: 31815114 DOI: 10.1155/2019/2576349] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
76 Eilard MS, Naredi P, Helmersson M, Hemmingsson O, Isaksson B, Lindell G, Sandström P, Strömberg C, Rizell M. Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma. HPB 2021;23:394-403. [DOI: 10.1016/j.hpb.2020.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O; Liver Cancer Study Group of Japan. Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. Br J Surg 2021;108:412-8. [PMID: 33793713 DOI: 10.1093/bjs/znaa109] [Reference Citation Analysis]
78 Wrighton PJ, Oderberg IM, Goessling W. There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2019;8:347-63. [PMID: 31108233 DOI: 10.1016/j.jcmgh.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
79 Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2019;26:73-81. [PMID: 30561147 DOI: 10.1002/jhbp.602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
80 Zou H, Wen Y, Yuan K, Miao X, Xiong L, Liu K. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int 2018;38:494-502. [DOI: 10.1111/liv.13514] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
81 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
82 Chiba T, Hiraoka A, Mikami S, Shinozaki M, Osaki Y, Obu M, Ohki T, Mita N, Ledesma D, Yoshihara N, Beusterien K, Amos K, Bridges JF, Yokosuka O. Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments. Patient Prefer Adherence 2019;13:637-47. [PMID: 31118587 DOI: 10.2147/PPA.S198363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
83 Beck M, Schirmacher P, Singer S. Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies. J Hepatol 2017;67:1051-61. [PMID: 28673770 DOI: 10.1016/j.jhep.2017.06.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
84 Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 2021;87:104663. [PMID: 33278635 DOI: 10.1016/j.meegid.2020.104663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
85 Chen Y, Chen HN, Wang K, Zhang L, Huang Z, Liu J, Zhang Z, Luo M, Lei Y, Peng Y, Zhou ZG, Wei Y, Huang C. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol 2019;70:66-77. [PMID: 30287340 DOI: 10.1016/j.jhep.2018.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
86 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
87 Ma XL, Qu XD, Yang WJ, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clin Chim Acta 2020;511:67-74. [PMID: 32979338 DOI: 10.1016/j.cca.2020.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, Chen M. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19:844-852. [PMID: 28070766 DOI: 10.1007/s12094-016-1611-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
89 Xu Q, Lin W, Tao C, Huang X, Li J. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells. Biochem Cell Biol 2020;98:362-9. [PMID: 32383983 DOI: 10.1139/bcb-2019-0227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Zhai Z, Fu Q, Liu C, Zhang X, Jia P, Xia P, Liu P, Liao S, Qin T, Zhang H. Emerging Roles Of hsa-circ-0046600 Targeting The miR-640/HIF-1α Signalling Pathway In The Progression Of HCC. Onco Targets Ther 2019;12:9291-302. [PMID: 31807009 DOI: 10.2147/OTT.S229514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
91 Allaire M, Rekik S, Layese R, Mumana A, Guyot E, Nkontchou G, Bourcier V, Grando V, Ziol M, Nahon P, Ganne-carrié N, Sutter O, Audureau E, Seror O, Nault J. Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. Digestive and Liver Disease 2019;51:86-94. [DOI: 10.1016/j.dld.2018.07.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
92 Huang A, Wang YP, Wang J, Fu PY, Zhang X, Cao Y, Fan J, Yang XR, Zhou J. Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. J Gastrointest Oncol 2020;11:112-20. [PMID: 32175113 DOI: 10.21037/jgo.2019.09.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Cai J, Tong Y, Huang L, Xia L, Guo H, Wu H, Kong X, Xia Q. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma. Carcinogenesis 2019;40:840-52. [DOI: 10.1093/carcin/bgz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
94 Kudo M. A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:530-3. [PMID: 32832511 DOI: 10.21037/hbsn-20-420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
96 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
97 Sun W, Cabrera R. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. J Gastrointest Cancer 2018;49:107-15. [PMID: 29453759 DOI: 10.1007/s12029-018-0065-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
98 Taketomi A. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol. 2016;21:213-218. [PMID: 26899258 DOI: 10.1007/s10147-016-0966-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
99 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
100 He Y, Dang Q, Li J, Zhang Q, Yu X, Xue M, Guo W. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging (Albany NY) 2020;12:965-77. [PMID: 31929113 DOI: 10.18632/aging.102669] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
101 Chen L, Chen S, Zhou Q, Cao Q, Dong Y, Feng S, Xiao H, Wang Y, Liu X, Liao G, Peng Z, Li B, Tan L, Ke Z, Li D, Peng B, Peng S, Zhu L, Liao B, Kuang M. Microvascular Invasion Status and Its Survival Impact in Hepatocellular Carcinoma Depend on Tissue Sampling Protocol. Ann Surg Oncol 2021. [PMID: 33751300 DOI: 10.1245/s10434-021-09673-w] [Reference Citation Analysis]
102 Hilmi M, Vienot A, Rousseau B, Neuzillet C. Immune Therapy for Liver Cancers. Cancers (Basel) 2019;12:E77. [PMID: 31892230 DOI: 10.3390/cancers12010077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
103 Zhang Y, Xi S, Chen J, Zhou D, Gao H, Zhou Z, Xu L, Chen M. Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. J Cancer 2017;8:2992-3000. [PMID: 28928891 DOI: 10.7150/jca.21038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
104 Jin J, Liu H, Jin M, Li W, Xu H, Wei F. Silencing of hsa_circ_0101145 reverses the epithelial-mesenchymal transition in hepatocellular carcinoma via regulation of the miR-548c-3p/LAMC2 axis. Aging (Albany NY) 2020;12:11623-35. [PMID: 32554866 DOI: 10.18632/aging.103324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
105 Dong ZR, Zou J, Sun D, Shi GM, Ke AW, Cai JB, Sun HC, Qiu SJ, Li T, Zhou J, Zhi XT, Fan J. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. J Cancer. 2017;8:3862-3867. [PMID: 29151974 DOI: 10.7150/jca.21313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
106 Kobayashi K, Uldry E, Kokudo T, Cristaudi A, Kawaguchi Y, Shirata C, Yamaguchi T, Dormond O, Duran R, Hasegawa K, Demartines N, Halkic N. Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. World J Surg 2021;45:2546-55. [PMID: 33891139 DOI: 10.1007/s00268-021-06111-6] [Reference Citation Analysis]
107 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
108 Guo L, Wang D, Li X, Liu B, Chen S, Li D, Xu H. Stiffness distribution in the ablated zone after radiofrequency ablation for liver: An ex-vivo study with a tissue elastometer. CH 2019;72:151-60. [DOI: 10.3233/ch-180404] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Augello C, Colombo F, Terrasi A, Trombetta E, Maggioni M, Porretti L, Rossi G, Guerneri S, Silipigni R, Bosari S, Vaira V. Expression of C19MC miRNAs in HCC associates with stem-cell features and the cancer-testis genes signature. Dig Liver Dis 2018;50:583-93. [PMID: 29673952 DOI: 10.1016/j.dld.2018.03.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
110 Luo Y, Fu Z, Wu P, Zheng D, Zhang X. The clinicopathological and prognostic significance of P27kip in hepatocellular carcinoma patients: A systemic review and meta-analysis. Gene 2020;734:144351. [PMID: 31982553 DOI: 10.1016/j.gene.2020.144351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Yang C, Wang S, Ruan H, Li B, Cheng Z, He J, Zuo Q, Yu C, Wang H, Lv Y, Gu D, Jin G, Yao M, Qin W, Jin H. Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:918-26. [PMID: 30854098 DOI: 10.7150/jca.27226] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
112 Li T, Lv M, Chen X, Yu Y, Zang G, Tang Z. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA. Drug Des Devel Ther 2019;13:1289-300. [PMID: 31118568 DOI: 10.2147/DDDT.S200610] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
113 Liao M, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52:624-634. [PMID: 28276833 DOI: 10.1080/00365521.2017.1292365] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
114 Gan X, Luo Y, Dai G, Lin J, Liu X, Zhang X, Li A. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage. Front Genet 2020;11:857. [PMID: 32849835 DOI: 10.3389/fgene.2020.00857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
115 Chen H, Kong M, Chen Y, Jiang Y, Wen M, Zhang X. Prognostic significance of miR-203 and ZEB1 expression in early-stage hepatocellular carcinoma. J Cancer 2021;12:4810-8. [PMID: 34234851 DOI: 10.7150/jca.57819] [Reference Citation Analysis]
116 You N, Tan Y, Zhou L, Huang X, Wang W, Wang L, Wu K, Mi N, Li J, Zheng L. Tg737 acts as a key driver of invasion and migration in liver cancer stem cells and correlates with poor prognosis in patients with hepatocellular carcinoma. Exp Cell Res 2017;358:217-26. [PMID: 28663060 DOI: 10.1016/j.yexcr.2017.06.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
117 Otedo A, Simbiri KO, Were V, Ongati O, Estambale BA. Risk factors for liver Cancer in HIV endemic areas of Western Kenya.Infect Agent Cancer. 2018;13:41. [PMID: 30607173 DOI: 10.1186/s13027-018-0214-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Yeh CM, Hsieh MJ, Yang JS, Yang SF, Chuang YT, Su SC, Liang MY, Chen MK, Lin CW. Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase-2 activation through the FAK/Src and ERK pathways. Environ Toxicol 2019;34:1085-93. [PMID: 31184425 DOI: 10.1002/tox.22809] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
119 Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, Dai Z, Tang Z, Fan J, Zhou J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis 2020;41:296-302. [PMID: 31535687 DOI: 10.1093/carcin/bgz154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 21.0] [Reference Citation Analysis]
120 Zhang XP, Gao YZ, Chen ZH, Wang K, Cheng YQ, Guo WX, Shi J, Zhong CQ, Zhang F, Cheng SQ. In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. J Cancer 2019;10:72-80. [PMID: 30662527 DOI: 10.7150/jca.27102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
121 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
122 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
123 Shiu JS, Hsieh MJ, Chiou HL, Wang HL, Yeh CB, Yang SF, Chou YE. Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics. Int J Med Sci 2018;15:1334-40. [PMID: 30275760 DOI: 10.7150/ijms.27059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
124 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
125 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma. J Dig Dis 2020;21:287-92. [PMID: 32315498 DOI: 10.1111/1751-2980.12866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
126 Zhang T, Huang S, Gu Y, Jiang X, Huang Z, Deng H, Huang J. Sequential and Simultaneous 4-Antenna Microwave Ablation in an Ex Vivo Bovine Liver Model. Cardiovasc Intervent Radiol 2019;42:1466-74. [DOI: 10.1007/s00270-019-02241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
127 Kamimura K, Yokoo T, Abe H, Sakai N, Nagoya T, Kobayashi Y, Ohtsuka M, Miura H, Sakamaki A, Kamimura H, Miyamura N, Nishina H, Terai S. Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E472. [PMID: 32085552 DOI: 10.3390/cancers12020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
128 Pei Y, Chen X, Zhang W. Liver resection for BCLC 0-A stage hepatocellular carcinoma: Does the time to surgery not impact the prognosis? Journal of Hepatology 2018;68:1101. [DOI: 10.1016/j.jhep.2017.12.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Xue Y, Jia X, Li L, Dong X, Ling J, Yuan J, Li Q. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway. Biochem Biophys Res Commun 2018;503:2885-91. [PMID: 30119889 DOI: 10.1016/j.bbrc.2018.08.063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
130 Xiao S, Huang S, Yang J. Overexpression of GIHCG is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11607-19. [PMID: 33209037 DOI: 10.2147/OTT.S271966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
131 Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733. [PMID: 27349488 DOI: 10.1016/j.jhep.2016.06.015] [Cited by in Crossref: 524] [Cited by in F6Publishing: 516] [Article Influence: 104.8] [Reference Citation Analysis]
132 Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Cleton A, Ploeger B. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. Eur J Pharm Sci. 2017;109S:S149-S153. [PMID: 28549676 DOI: 10.1016/j.ejps.2017.05.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
133 Clark P. Serum markers for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;8:29-33. [PMID: 31041059 DOI: 10.1002/cld.565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
134 Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis 2021;12:691. [PMID: 34244479 DOI: 10.1038/s41419-021-03973-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. World J Gastroenterol 2018; 24(37): 4224-4229 [PMID: 30310255 DOI: 10.3748/wjg.v24.i37.4224] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
136 Bak-Fredslund KP, Keiding S, Villadsen GE, Kramer S, Schlander S, Sørensen M. [18 F]-Fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma. Liver Int 2020;40:447-55. [PMID: 31705784 DOI: 10.1111/liv.14293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Tinguely P, Paolucci I, Ruiter SJS, Weber S, de Jong KP, Candinas D, Freedman J, Engstrand J. Stereotactic and Robotic Minimally Invasive Thermal Ablation of Malignant Liver Tumors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:713685. [PMID: 34631539 DOI: 10.3389/fonc.2021.713685] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Chang CY, Hsieh WY, Chau GY, Chen PH, Su CW, Hou MC, Lei HJ, Huo TI, Huang YH, Lin HC, Wu JC. Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2018;30:1368-77. [PMID: 29994873 DOI: 10.1097/MEG.0000000000001193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
139 Xu M, Liu Z, Wang C, Yao B, Zheng X. EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling. Oncotarget 2017;8:66154-68. [PMID: 29029500 DOI: 10.18632/oncotarget.19825] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
140 Labeur TA, Takkenberg RB, Klümpen HJ, van Delden OM. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2019;42:230-8. [PMID: 30488302 DOI: 10.1007/s00270-018-2118-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
141 Eferl R, Trauner M. Chromosomal instability in HCC: a key function for checkpoint kinase 2. Gut 2018;67:204-5. [PMID: 28476916 DOI: 10.1136/gutjnl-2017-314101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Pei Y, Zhang Z, Mba'nbo-Koumpa AA, Chen X, Zhang W. Improved survival following splenectomy combined with curative treatments for hepatocellular carcinoma in Child B patients: A propensity score matching study. Hepatol Res 2019;49:177-88. [PMID: 30347506 DOI: 10.1111/hepr.13276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
143 Cao W, Sharma M, Imam R, Yu J. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. American Journal of Clinical Pathology 2019;152:647-55. [DOI: 10.1093/ajcp/aqz086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
144 Ogbodu RO, Nitzsche B, Ma A, Atilla D, Gürek AG, Höpfner M. Photodynamic therapy of hepatocellular carcinoma using tetra-triethyleneoxysulfonyl zinc phthalocyanine as photosensitizer. Journal of Photochemistry and Photobiology B: Biology 2020;208:111915. [DOI: 10.1016/j.jphotobiol.2020.111915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
145 Labeur TA, Runge JH, Klompenhouwer EG, Klümpen H, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol 2019;44:2740-50. [DOI: 10.1007/s00261-019-02030-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
146 Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;311:G203-9. [DOI: 10.1152/ajpgi.00193.2016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
147 Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T, Unno M, Kamei T, Gonda K. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol 2021;38:60. [PMID: 33881631 DOI: 10.1007/s12032-021-01503-z] [Reference Citation Analysis]
148 Liu L, Wang B, Han Q, Zhen C, Li J, Qu X, Wang F, Kong X, Zheng L. Bioinformatic Analysis to Identify a Multi-mRNA Signature for the Prediction of Metastasis in Hepatocellular Carcinoma. DNA Cell Biol 2020;39:2028-39. [PMID: 33147069 DOI: 10.1089/dna.2020.5513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Wang M, Huang S, Chen Z, Han Z, Li K, Chen C, Wu G, Zhao Y. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer 2020;20:1136. [PMID: 33228611 DOI: 10.1186/s12885-020-07625-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
151 Kokudo T, Hasegawa K, Kokudo N. Reply. Hepatology 2017;67:806-7. [DOI: 10.1002/hep.29673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Taddei TH, Lo Re V 3rd, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Curr HIV/AIDS Rep 2016;13:269-78. [PMID: 27614654 DOI: 10.1007/s11904-016-0327-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
153 Wu Z, Wu J, Fang P, Kan S. Puerarin increases the chemosensitivity of hepatocellular carcinoma cells. Oncol Lett 2017;14:3006-10. [PMID: 28928838 DOI: 10.3892/ol.2017.6524] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
154 Tan L, Chen S, Wei G, Li Y, Liao J, Jin H, Zou Y, Huang M, Peng Z, Guo Y, Peng S, Xu L, Kuang M. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Letters 2019;460:29-40. [DOI: 10.1016/j.canlet.2019.05.041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
155 Xu W, Guo R, Xu G, Sun L, Hu D, Xu H, Yang H, Sang X, Lu X, Mao Y. Management of intrahepatic recurrence after resection for hepatocellular carcinoma exceeding the barcelona clinic liver cancer criteria. Oncotarget 2017;8:110406-14. [PMID: 29299157 DOI: 10.18632/oncotarget.22779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
156 Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, Shen YH, Cai JB, Yang Z, Zhou J, Fan J, Sun HC, Kuang M, Huang C. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. J Hematol Oncol 2018;11:28. [PMID: 29482578 DOI: 10.1186/s13045-018-0573-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
157 Qi LN, Ma L, Wu FX, Chen YY, Xing WT, Jiang ZJ, Zhong JH, Chen ZS, Gong WF, Ye JZ, Li HH, Shang JJ, Xiang BD, Li LQ. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. Hepatol Int 2021;15:114-26. [PMID: 33495903 DOI: 10.1007/s12072-020-10130-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
159 Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, Tani CM, Chagas AL, Pfiffer T, Hoff P, Carrilho FJ, Alves de Mattos A. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Annals of Hepatology 2017;16:263-8. [DOI: 10.5604/16652681.1231587] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
160 Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol 2018; 24(17): 1839-1858 [PMID: 29740200 DOI: 10.3748/wjg.v24.i17.1839] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
161 Liu Q, Zhou B, Liao R, Zhou X, Yan X. PIAS4, upregulated in hepatocellular carcinoma, promotes tumorigenicity and metastasis. J Cell Biochem 2020;121:3372-81. [PMID: 31943317 DOI: 10.1002/jcb.29610] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66. [PMID: 27932229 DOI: 10.1016/s0140-6736(16)32453-9] [Cited by in Crossref: 1429] [Cited by in F6Publishing: 879] [Article Influence: 285.8] [Reference Citation Analysis]
163 Wu L, Wu J, Shang A, Yang M, Li L, Yu J, Xu L, Wang C, Wang W, Zhu J, Lu W. miR-124 inhibits progression of hepatocarcinoma by targeting KLF4 and promises a novel diagnostic marker. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:159-67. [DOI: 10.1080/21691401.2017.1415918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
164 Zou H, Wang F, Zhou JJ, Liu X, He Q, Wang C, Zheng YW, Wen Y, Xiong L. Application of photodynamic therapy for liver malignancies. J Gastrointest Oncol 2020;11:431-42. [PMID: 32399283 DOI: 10.21037/jgo.2020.02.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
165 Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, Tao L, Zheng J, Cai L, Wang Y, Liang X, Cai X. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal Transduct Target Ther 2021;6:190. [PMID: 34001851 DOI: 10.1038/s41392-021-00594-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
166 Wang J, Tan Q, Wang W, Yu J. Mechanism of the Regulatory Effect of Overexpression of circMTO1 on Proliferation and Apoptosis of Hepatoma Cells via miR-9-5p/NOX4 Axis. Cancer Manag Res 2020;12:3915-25. [PMID: 32547227 DOI: 10.2147/CMAR.S240719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
167 Poch FGM, Neizert CA, Geyer B, Gemeinhardt O, Niehues SM, Vahldiek JL, Bressem KK, Lehmann KS. Perivascular vital cells in the ablation center after multibipolar radiofrequency ablation in an in vivo porcine model. Sci Rep 2021;11:13886. [PMID: 34230573 DOI: 10.1038/s41598-021-93406-2] [Reference Citation Analysis]
168 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
169 Muhammad Irham L, Chou WH, Wang YS, Adikusuma W, Sung-Ching Wong H, Aryani Perwitasari D, Huang WC, Chen BK, Yang HI, Chang WC. Evaluation for the Genetic Association between Store-Operated Calcium Influx Pathway (STIM1 and ORAI1) and Human Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection. Biology (Basel) 2020;9:E388. [PMID: 33182378 DOI: 10.3390/biology9110388] [Reference Citation Analysis]
170 Awad SM, Taha M, Omar M, Khalil A. The implication of genetic variation in the complement C3 allotypes on the first-year allograft outcome after live donor liver transplantation. Transpl Immunol 2020;60:101294. [PMID: 32305505 DOI: 10.1016/j.trim.2020.101294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Yoo JJ, Yu SJ, Lee B, Cho EJ, Lee JH, Kim SG, Kim YJ, Kim YS, Yoon JH. Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut Liver 2020;14:377-86. [PMID: 31533399 DOI: 10.5009/gnl19112] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Chen Y, Li H, Chen D, Jiang X, Wang W, Li D, Shan H. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression. Dig Dis Sci 2021. [PMID: 34383201 DOI: 10.1007/s10620-021-07202-z] [Reference Citation Analysis]
173 Li R, Yanjiao G, Wubin H, Yue W, Jianhua H, Huachuan Z, Rongjian S, Zhidong L. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells. Oncotarget 2017;8:19354-64. [PMID: 28423613 DOI: 10.18632/oncotarget.15223] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
174 Liu J, Jiang J, Mo J, Liu D, Cao D, Wang H, He Y, Wang H. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma. Hepatology 2019;69:196-208. [PMID: 30070373 DOI: 10.1002/hep.30146] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
175 Shi F, Lian S, Mai Q, Mo Z, Zhuang W, Cui W, Shen L, Chen M, Wu P, Chen X. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria. Eur Radiol. 2020;30:2454-2462. [PMID: 32002636 DOI: 10.1007/s00330-019-06604-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
176 Cheung PF, Yip CW, Ng LW, Lo KW, Chow C, Chan KF, Cheung TT, Cheung ST. Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line. Cancer Cell Int 2016;16:41. [PMID: 27279800 DOI: 10.1186/s12935-016-0322-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
177 Ji Y, Chen H, Gow W, Ma L, Jin Y, Hui B, Yang Z, Wang Z. Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma. Oncol Lett 2020;20:208. [PMID: 32963614 DOI: 10.3892/ol.2020.12071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
178 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
179 Fabregat I, Caballero-Díaz D. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. Front Oncol 2018;8:357. [PMID: 30250825 DOI: 10.3389/fonc.2018.00357] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 31.3] [Reference Citation Analysis]
180 Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N. Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:7568742. [PMID: 30425976 DOI: 10.1155/2018/7568742] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
181 Zhou C, Hu C, Wang B, Fan S, Jin W. Curcumin Suppresses Cell Proliferation, Migration, and Invasion Through Modulating miR-21-5p/SOX6 Axis in Hepatocellular Carcinoma. Cancer Biother Radiopharm 2020. [PMID: 32757994 DOI: 10.1089/cbr.2020.3734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
182 Chen SL, Xiao H, Xie ZL, Shen JX, Chen ZB, Wang YQ, Li B, Peng ZW, Kuang M, Lai JM, Peng S. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC. Eur Radiol 2020;30:3473-85. [PMID: 32048035 DOI: 10.1007/s00330-019-06640-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
183 Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med. 2017;15:200. [PMID: 29121925 DOI: 10.1186/s12916-017-0966-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
184 Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointest Endosc. 2018;88:230-239.e2. [PMID: 29317268 DOI: 10.1016/j.gie.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
185 Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma: Molecular targeted therapy for liver cancer. Hepatol Res 2018;48:597-607. [DOI: 10.1111/hepr.13181] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
186 Ma XL, Sun YF, Wang BL, Shen MN, Zhou Y, Chen JW, Hu B, Gong ZJ, Zhang X, Cao Y, Pan BS, Zhou J, Fan J, Guo W, Yang XR. Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. BMC Cancer 2019;19:760. [PMID: 31370822 DOI: 10.1186/s12885-019-5963-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
187 Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Craxì A, Di Marco V, Cammà C, Calvaruso V, Petta S, Cabbibbo G, Colletti P, Mazzola G, Cascio A, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Sanfilippo A, Ficalora A, Madonia S, Tinè F, Malizia G, Latteri F, Maida M, Cartabellotta F, Vassallo R, Cacciola I, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Mondello L, Smedile A, D’andrea S, Bertino G, Ardiri A, Frazzetto E, Rigano G, Montineri A, Larocca L, Cacopardo B, Benanti F, Russello M, Benigno R, Bellia A, Iacobello C, Davì A, Di Rosolini M, Digiacomo A, Fuduli G, Scifo G, Distefano M, Portelli V, Savalli F, Scalici I, Gioia G, Magro A, Alaimo G, Alinovi M, Salvo A, Averna A, Lomonaco F, Guarneri L, Maffeo F, Falzone E, Pulvirenti F. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-421.e4. [DOI: 10.1053/j.gastro.2018.04.008] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 51.0] [Reference Citation Analysis]
188 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 29.5] [Reference Citation Analysis]
189 Lucatelli P, Argirò R, Ginanni Corradini S, Saba L, Cirelli C, Fanelli F, Ricci C, Levi Sandri GB, Catalano C, Bezzi M. Comparison of Image Quality and Diagnostic Performance of Cone-Beam CT during Drug-Eluting Embolic Transarterial Chemoembolization and Multidetector CT in the Detection of Hepatocellular Carcinoma. J Vasc Interv Radiol 2017;28:978-86. [PMID: 28495451 DOI: 10.1016/j.jvir.2017.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
190 Tang Y, Chen J, Li J, Zheng Y, Zhong X, Huang S, Chen B, Peng B, Zou X, Chen X. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. Phytomedicine 2021;86:153563. [PMID: 33951569 DOI: 10.1016/j.phymed.2021.153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C, Nicolay NH, Ihorst G, Bamberg F, Thimme R, Grosu AL, Gkika E. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021;11:653141. [PMID: 33816309 DOI: 10.3389/fonc.2021.653141] [Reference Citation Analysis]
193 Xu X, Pu X, Jiang L, Huang Y, Yan L, Yang J, Wen T, Li B, Wu H, Wang W. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria. J Cancer Res Clin Oncol 2021;147:607-18. [PMID: 32852635 DOI: 10.1007/s00432-020-03364-x] [Reference Citation Analysis]
194 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999-1008. [PMID: 28687477 DOI: 10.1016/j.jhep.2017.06.026] [Cited by in Crossref: 234] [Cited by in F6Publishing: 234] [Article Influence: 58.5] [Reference Citation Analysis]
196 Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, Scaffaro LA, Chedid AD. Hepatocellular carcinoma: Diagnosis and operative management. Arq Bras Cir Dig. 2017;30:272-278. [PMID: 29340553 DOI: 10.1590/0102-6720201700040011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
197 Xiao S, Hu Z, He Y, Jin H, Yang Y, Chen L, Chen Q, Luo Q, Liu J. Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors. Biomed Res Int 2020;2020:3050148. [PMID: 32090074 DOI: 10.1155/2020/3050148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Yue X, Jiang Q, Hu X, Cen C, Song S, Qian K, Lu Y, Yang M, Li Q, Han P. Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization. Sci Rep 2021;11:11127. [PMID: 34045528 DOI: 10.1038/s41598-021-90508-9] [Reference Citation Analysis]
199 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 27.5] [Reference Citation Analysis]
200 Shi Z, Song T, Wan Y, Xie J, Yan Y, Shi K, Du Y, Shang L. A systematic review and meta-analysis of traditional insect Chinese medicines combined chemotherapy for non-surgical hepatocellular carcinoma therapy. Sci Rep 2017;7:4355. [PMID: 28659623 DOI: 10.1038/s41598-017-04351-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
201 Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther 2018;47:95-103. [PMID: 29034998 DOI: 10.1111/apt.14356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
202 Wang T, Chen W, Xu G, Zhang B, Wei S, Hu J, Zhang K. A universal strategy designed for selecting bench-to-bedside aptamers to serum and validated in hepatocellular carcinoma diagnosis. Microchemical Journal 2019;150:104152. [DOI: 10.1016/j.microc.2019.104152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Wang XH, Liao B, Hu WJ, Tu CX, Xiang CL, Hao SH, Mao XH, Qiu XM, Yang XJ, Yue X, Kuang M, Peng BG, Li SQ. Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus. Oncologist 2020;25:e1552-61. [PMID: 32663354 DOI: 10.1634/theoncologist.2019-0766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
204 Rao S, Zaidi S, Banerjee J, Jogunoori W, Sebastian R, Mishra B, Nguyen BN, Wu RC, White J, Deng C, Amdur R, Li S, Mishra L. Transforming growth factor-β in liver cancer stem cells and regeneration. Hepatol Commun 2017;1:477-93. [PMID: 29404474 DOI: 10.1002/hep4.1062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
205 Liu YZ, Lu HL, Qi XM, Xing GZ, Wang X, Yu P, Liu L, Yang FF, Ding XL, Zhang ZA, Deng ZP, Gong LK, Ren J. Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats. Acta Pharmacol Sin 2021. [PMID: 33686245 DOI: 10.1038/s41401-021-00622-7] [Reference Citation Analysis]
206 Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661-669. [PMID: 29543938 DOI: 10.1001/jamaoncol.2017.5847] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 65.0] [Reference Citation Analysis]
207 Gao C, Wen Y, Jiang F, Gu X, Zhu X. Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA -140-3p. Bioengineered 2021;12:1890-901. [PMID: 34002672 DOI: 10.1080/21655979.2021.1926195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Chong CC, Chan AW, Wong J, Chu CM, Chan SL, Lee KF, Yu SC, To KF, Johnson P, Lai PB. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Surgeon. 2018;16:163-170. [PMID: 28807570 DOI: 10.1016/j.surge.2017.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
209 Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel). 2019;11. [PMID: 31370183 DOI: 10.3390/cancers11081084] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 22.5] [Reference Citation Analysis]
211 Wörns MA, Galle PR. Patient prioritisation in HCC treatment: All (good) things come in threes. J Hepatol 2018;68:1311-2. [PMID: 29496352 DOI: 10.1016/j.jhep.2017.11.035] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
213 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Shibata O, Kamimura K, Ko M, Sakai N, Abe H, Morita S, Mizusawa T, Sato H, Sakamaki A, Terai S. Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. Intern Med 2021;60:1709-15. [PMID: 33390501 DOI: 10.2169/internalmedicine.6580-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Xie H, Liu S, Zhang Z, Chen P, Tao Y. A novel seven-gene signature as Prognostic Biomarker in Hepatocellular Carcinoma. J Cancer 2020;11:5768-81. [PMID: 32913470 DOI: 10.7150/jca.44573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Liu J, Li W, Zhao H. CFHR3 is a potential novel biomarker for hepatocellular carcinoma. J Cell Biochem 2020;121:2970-80. [DOI: 10.1002/jcb.29551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
217 Andreozzi A, Iasiello M, Tucci C. An overview of mathematical models and modulated-heating protocols for thermal ablation. Elsevier; 2020. pp. 489-541. [DOI: 10.1016/bs.aiht.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 526.7] [Reference Citation Analysis]
219 Rungsakulkij N, Mingphruedhi S, Suragul W, Tangtawee P, Muangkaew P, Aeesoa S. Platelet-to-Lymphocyte Ratio and Large Tumor Size Predict Microvascular Invasion after Resection for Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2018;19:3435-41. [PMID: 30583666 DOI: 10.31557/APJCP.2018.19.12.3435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
220 Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:167-76. [PMID: 33791252 DOI: 10.2147/JHC.S298538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
221 Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int 2019;19:138. [PMID: 31139015 DOI: 10.1186/s12935-019-0858-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 58] [Article Influence: 24.5] [Reference Citation Analysis]
222 De Toni EN, Gerbes AL. Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient. Gastroenterology. 2017;152:1631-1633. [PMID: 28384452 DOI: 10.1053/j.gastro.2017.01.063] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
223 Li J, Huang L, Yan J, Qiu M, Yan Y. Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. ANZ J Surg 2018;88:E713-7. [PMID: 29363237 DOI: 10.1111/ans.14381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
224 Pu J, Wang J, Wei H, Lu T, Wu X, Wu Y, Shao Z, Luo C, Lu Y. lncRNA MAGI2-AS3 Prevents the Development of HCC via Recruiting KDM1A and Promoting H3K4me2 Demethylation of the RACGAP1 Promoter. Mol Ther Nucleic Acids. 2019;18:351-362. [PMID: 31629962 DOI: 10.1016/j.omtn.2019.08.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
225 Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S, Jian Z. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119:9419-9432. [PMID: 30015355 DOI: 10.1002/jcb.27259] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 22.3] [Reference Citation Analysis]
226 Wang Z, Embaye KS, Yang Q, Qin L, Zhang C, Liu L, Zhan X, Zhang F, Wang X, Qin S. A Novel Metabolism-Related Signature as a Candidate Prognostic Biomarker for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:119-32. [PMID: 33758763 DOI: 10.2147/JHC.S294108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
227 Kim HS, Yi NJ, Kim JM, Joh JW, Lee KW, Suh KS. Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection. Ann Surg Treat Res 2021;101:85-92. [PMID: 34386457 DOI: 10.4174/astr.2021.101.2.85] [Reference Citation Analysis]
228 Actor JA, Fuentes DT, Rivière B. Identification of Kernels in a Convolutional Neural Network: Connections Between Level Set Equation and Deep Learning for Image Segmentation. Proc SPIE Int Soc Opt Eng 2020;11313:1131317. [PMID: 32377028 DOI: 10.1117/12.2548871] [Reference Citation Analysis]
229 Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events. Cancers (Basel) 2020;12:E1010. [PMID: 32325921 DOI: 10.3390/cancers12041010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
230 Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A, Silva M. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019; 25(27): 3607-3618 [PMID: 31367160 DOI: 10.3748/wjg.v25.i27.3607] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
231 Pipa-Muñiz M, Castells L, Pascual S, Fernández-Castroagudín J, Díez-Miranda I, Irurzun J, Díaz-Beveridge R, Senosiaín M, Arenas J, de la Mata M, Turnes J, Monge-Romero MI, Pérez-Enguix D, Bustamante-Schneider J, Otegui N, Molina-Pérez E, Rodríguez-Menéndez JE, Varela M. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. Gastroenterol Hepatol 2017;40:515-24. [PMID: 28676199 DOI: 10.1016/j.gastrohep.2017.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
232 Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, Kang TW, Ku YM, Lee SL, Park YS, Yoon JH, Kim SH, Choi MH. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer 2017;17:877. [PMID: 29268722 DOI: 10.1186/s12885-017-3819-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
233 Cai Z, Zhang J, He Y, Xia L, Dong X, Chen G, Zhou Y, Hu X, Zhong S, Wang Y, Chen H, Xie D, Liu X, Liu J. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO Open 2021;6:100021. [PMID: 33508734 DOI: 10.1016/j.esmoop.2020.100021] [Reference Citation Analysis]
234 Sotiropoulos GC, Machairas N, Kostakis ID, Stamopoulos P, Charalampoudis P, Kykalos S, Kouraklis G, Mantas D. Early Experience in Starting a Laparoscopic Liver Resection Program in Greece. JSLS 2017;21:e2016. [PMID: 28701858 DOI: 10.4293/JSLS.2016.00110] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
235 Tada T, Kumada T, Toyoda H, Yasuda S, Koyabu T, Nakashima M. Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. Nutr Cancer 2019;71:1132-41. [PMID: 30955354 DOI: 10.1080/01635581.2019.1597905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
236 Liu F, Liao Z, Song J, Yuan C, Liu Y, Zhang H, Pan Y, Zhang Z, Zhang B. Genome-wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma. J Cell Biochem 2020;121:2582-94. [PMID: 31692036 DOI: 10.1002/jcb.29480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
237 Zhang L, Xia W, Yan ZP, Sun JH, Zhong BY, Hou ZH, Yang MJ, Zhou GH, Wang WS, Zhao XY, Jian JM, Huang P, Zhang R, Zhang S, Zhang JY, Li Z, Zhu XL, Gao X, Ni CF. Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. Front Oncol. 2020;10:593292. [PMID: 33102242 DOI: 10.3389/fonc.2020.593292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
238 Xu QG, Yu J, Guo XG, Hou GJ, Yuan SX, Yang Y, Yang Y, Liu H, Pan ZY, Yang F, Gu FM, Zhou WP. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma. Mol Oncol 2018;12:936-52. [PMID: 29689643 DOI: 10.1002/1878-0261.12306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
239 Tang X, Shu Z, Zhang W, Cheng L, Yu J, Zhang M, Zheng S. Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. Ann Transl Med 2019;7:528. [PMID: 31807510 DOI: 10.21037/atm.2019.09.122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
240 Zhou Y, He L, Huang Y, Chen S, Wu P, Ye W, Liu Z, Liang C. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2017;42:1695-1704. [PMID: 28180924 DOI: 10.1007/s00261-017-1072-0] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 25.3] [Reference Citation Analysis]
241 Cui W, Fan W, Zhang Q, Wen J, Huang Y, Yang J, Li J, Wang Y. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. Oncotarget 2017;8:79165-74. [PMID: 29108296 DOI: 10.18632/oncotarget.16298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
242 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 32.5] [Reference Citation Analysis]
243 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
244 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 21.0] [Reference Citation Analysis]
245 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
247 Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T, Reinicke D, Garcia M, Luc A, Baumann C, Ayav A, Laurent V, Hollenbach M, Ripoll C, Guéant-Rodriguez RM, Namour F, Zipprich A, Fleischhacker M, Bronowicki JP, Guéant JL. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine 2018;30:138-47. [PMID: 29627389 DOI: 10.1016/j.ebiom.2018.03.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 17.0] [Reference Citation Analysis]
248 Salgia R, Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8. [PMID: 34386204 DOI: 10.1002/cld.1068] [Reference Citation Analysis]
249 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
250 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
251 Zhang XP, Zhou TF, Feng JK, Sun ZY, Zhen ZJ, Zhou D, Zhang F, Hu YR, Zhong CQ, Chen ZH, Chai ZT, Wang K, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Association of Preoperative Coagulability With Incidence and Extent of Portal Vein Tumor Thrombus and Survival Outcomes in Hepatocellular Carcinoma After Hepatectomy: A Large-Scale, Multicenter Study. Front Oncol 2021;11:697073. [PMID: 34395264 DOI: 10.3389/fonc.2021.697073] [Reference Citation Analysis]
252 Sanyal AJ, Mathurin P, Nagy LA. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1695-1697. [PMID: 27155520 DOI: 10.1053/j.gastro.2016.04.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J Pathol. 2018;245:297-310. [PMID: 29604056 DOI: 10.1002/path.5083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
254 Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22:5928-5938. [PMID: 30247807 DOI: 10.1111/jcmm.13863] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 18.7] [Reference Citation Analysis]
255 Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Yeong CH. Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis. Pharmaceutics 2019;11:E596. [PMID: 31718079 DOI: 10.3390/pharmaceutics11110596] [Reference Citation Analysis]
256 Dou D, Zhang ZY, Wu ZY, Qiu XD, Zhong XG. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:5497041. [PMID: 32904600 DOI: 10.1155/2020/5497041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
257 Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol 2019;2019:6298502. [PMID: 31636667 DOI: 10.1155/2019/6298502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
258 Ren A, Zhao P, Yang D, Du J, Wang Z, Yang Z. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017: LI-RADS v2018 of MRI for Diagnosing HCC. J Magn Reson Imaging 2019;50:746-55. [DOI: 10.1002/jmri.26640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
259 Rodríguez-Hernández MA, González R, de la Rosa ÁJ, Gallego P, Ordóñez R, Navarro-Villarán E, Contreras L, Rodríguez-Arribas M, González-Gallego J, Álamo-Martínez JM, Marín-Gómez LM, Del Campo JA, Quiles JL, Fuentes JM, de la Cruz J, Mauriz JL, Padillo FJ, Muntané J. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. J Cell Physiol 2018;234:692-708. [PMID: 30132846 DOI: 10.1002/jcp.26855] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
260 Li Z, Hu Y, Zeng Q, Wang H, Yan J, Li H, Yu Z. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int 2019;19:211. [PMID: 31413665 DOI: 10.1186/s12935-019-0926-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
261 Lewis S, Peti S, Hectors SJ, King M, Rosen A, Kamath A, Putra J, Thung S, Taouli B. Volumetric quantitative histogram analysis using diffusion-weighted magnetic resonance imaging to differentiate HCC from other primary liver cancers. Abdom Radiol (NY) 2019;44:912-22. [PMID: 30712136 DOI: 10.1007/s00261-019-01906-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
262 Zhang XP, Wang K, Wei XB, Li LQ, Sun HC, Wen TF, Chai ZT, Chen ZH, Shi J, Guo WX, Xie D, Cong WM, Wu MC, Lau WY, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. Oncologist 2019;24:e1476-88. [PMID: 31138726 DOI: 10.1634/theoncologist.2018-0868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
263 Liu S, Tang Q, Huang J, Zhan M, Zhao W, Yang X, Li Y, Qiu L, Zhang F, Lu L, He X. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging (Albany NY) 2021;13:11257-80. [PMID: 33820866 DOI: 10.18632/aging.202811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Laskar DB, Ilyas G, Diaz D, Shao C. Shoulder Mass as the Initial Presentation of Metastatic Hepatocellular Carcinoma. ACG Case Rep J 2017;4:e72. [PMID: 28584845 DOI: 10.14309/crj.2017.72] [Reference Citation Analysis]
265 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
266 Li KY, Zhang SM, Shi CX, Tang KL, Huang JZ. Effect of prophylactic transcatheter arterial chemoembolization on hepatocellular carcinoma with microvascular invasion after R0 resection. A case-control study. Sao Paulo Med J 2020;138:60-3. [PMID: 32321107 DOI: 10.1590/1516-3180.2019.0042.R1.05072019] [Reference Citation Analysis]
267 Vitale A, Farinati F, Noaro G, Burra P, Pawlik TM, Bucci L, Giannini EG, Faggiano C, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati‐baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Fornari F, Marignani M, Vicari S, Bortolini E, Cozzolongo R, Grasso A, Aliberti C, Bernardi M, Frigo AC, Borzio M, Trevisani F, Cillo U; on behalf of the Italian Liver Cancer (ITA.LI.CA) group. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology 2018;68:1232-44. [DOI: 10.1002/hep.30185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
268 Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib. PLoS One 2020;15:e0244370. [PMID: 33351844 DOI: 10.1371/journal.pone.0244370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
269 Crosas-Molist E, Bertran E, Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno V, Fabregat I. The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination. Oncogene 2017;36:3002-14. [PMID: 27941881 DOI: 10.1038/onc.2016.454] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
270 Jabeen K, Malik U, Mansoor S, Shahzad S, Zahid S, Javed A. Effect of oxidative stress and calcium deregulation on FAM26F (CALHM6) expression during hepatitis B virus infection. BMC Infect Dis 2021;21:228. [PMID: 33639860 DOI: 10.1186/s12879-021-05888-0] [Reference Citation Analysis]
271 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
272 Zhang XP, Wang K, Gao YZ, Wei XB, Lu CD, Chai ZT, Zhen ZJ, Li J, Yang DH, Zhou D, Fan RF, Yan ML, Xia YJ, Liu B, Huang YQ, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Cheng ZH, Wu MC, Lau WY, Cheng SQ; Chinese National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus. Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion. Br J Surg 2020;107:865-77. [PMID: 32246475 DOI: 10.1002/bjs.11524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
273 Yang S, Cai H, Hu B, Tu J. LncRNA SAMMSON negatively regulates miR-9-3p in hepatocellular carcinoma cells and has prognostic values. Biosci Rep 2019;39:BSR20190615. [PMID: 31164410 DOI: 10.1042/BSR20190615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
274 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection. Infect Agent Cancer 2018;13:20. [PMID: 29930697 DOI: 10.1186/s13027-018-0192-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
275 Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver Int 2019;39:1478-89. [PMID: 31131974 DOI: 10.1111/liv.14154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
276 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
277 Kawaguchi Y, Lillemoe HA, Vauthey JN. Surgical Resection: Old Dog, Any New Tricks? Clin Liver Dis 2020;24:637-55. [PMID: 33012450 DOI: 10.1016/j.cld.2020.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
278 Chen G, Cai Z, Li Z, Dong X, Xu H, Lin J, Chen L, Zhang H, Liu X, Liu J. Clonal evolution in long-term follow-up patients with hepatocellular carcinoma. Int J Cancer. 2018;143:2862-2870. [PMID: 30183077 DOI: 10.1002/ijc.31844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
279 Kokudo T, Hasegawa K, Shirata C, Tanimoto M, Ishizawa T, Kaneko J, Akamatsu N, Arita J, Demartines N, Uldry E, Kokudo N, Halkic N. Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer 2019;8:447-56. [PMID: 31799202 DOI: 10.1159/000501368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
280 Shi F, Li G, Zhou Z, Xu R, Li W, Zhuang W, Chen Z, Chen X. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. Oncotarget 2017;8:109791-8. [PMID: 29312649 DOI: 10.18632/oncotarget.22308] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
281 Lin S, Ye F, Rong W, Song Y, Wu F, Liu Y, Zheng Y, Siqin T, Zhang K, Wang L, Wu J. Nomogram to Assist in Surgical Plan for Hepatocellular Carcinoma: a Prediction Model for Microvascular Invasion. J Gastrointest Surg 2019;23:2372-82. [PMID: 30820799 DOI: 10.1007/s11605-019-04140-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
282 Zhang W, Xu AH, Wang W, Wu YH, Sun QL, Shu C. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. BMC Cancer 2019;19:1041. [PMID: 31690274 DOI: 10.1186/s12885-019-6265-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
283 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status. Medicine (Baltimore) 2019;98:e17692. [PMID: 31689794 DOI: 10.1097/MD.0000000000017692] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
284 Qi W, Zhang Q, Xu Y, Wang X, Yu F, Zhang Y, Zhao P, Guo H, Zhou C, Wang Z, Sun Y, Liu L, Xuan W, Wang J. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation. J Viral Hepat 2020;27:387-96. [PMID: 31755220 DOI: 10.1111/jvh.13236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
285 Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018;18:138. [PMID: 30180810 DOI: 10.1186/s12876-018-0849-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
286 Gavini J, Dommann N, Jakob MO, Keogh A, Bouchez LC, Karkampouna S, Julio MK, Medova M, Zimmer Y, Schläfli AM, Tschan MP, Candinas D, Stroka D, Banz V. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis 2019;10:749. [PMID: 31582741 DOI: 10.1038/s41419-019-1989-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
287 Xu QG, Yuan SX, Tao QF, Yu J, Cai J, Yang Y, Guo XG, Lin KY, Ma JZ, Dai DS, Wang ZG, Gu FM, Zhao LH, Li LQ, Liu JF, Sun SH, Zang YJ, Liu H, Yang F, Zhou WP. A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma. J Hepatol 2019;70:904-17. [PMID: 30654066 DOI: 10.1016/j.jhep.2019.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
288 Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state: Liver Cancer in the United States. CA: A Cancer Journal for Clinicians 2017;67:273-89. [DOI: 10.3322/caac.21402] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
289 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
290 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
291 Zhang H, Song Y, Li L, Zhang S, Wu Q, Mei W, Liu H, Wang X. Phenanthroimidazole derivatives act as potent inducer of autophagy by activating DNA damage pathway. Bioorganic Chemistry 2019;88:102940. [DOI: 10.1016/j.bioorg.2019.102940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
292 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
293 Gupta P, Maralakunte M, Kumar-M P, Chandel K, Chaluvashetty SB, Bhujade H, Kalra N, Sandhu MS. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol 2021;31:5400-8. [PMID: 33439319 DOI: 10.1007/s00330-020-07610-1] [Reference Citation Analysis]
294 Kamioka H, Edaki K, Kasahara H, Tomono T, Yano K, Ogihara T. Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells. J Pharm Pharmacol 2021:rgab051. [PMID: 34313784 DOI: 10.1093/jpp/rgab051] [Reference Citation Analysis]
295 Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.Int J Mol Sci. 2019;20. [PMID: 30650598 DOI: 10.3390/ijms20020336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
296 Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W. Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis. Cancer Manag Res 2019;11:9321-30. [PMID: 31802950 DOI: 10.2147/CMAR.S223271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Xu H, Liu F, Hao X, Wei Y, Li B, Wen T, Wang W, Yang J. Laparoscopically anatomical versus non-anatomical liver resection for large hepatocellular carcinoma. HPB 2020;22:136-43. [DOI: 10.1016/j.hpb.2019.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
298 Li H, Li S, Geng J, Zhao S, Tan K, Yang Z, Feng D, Liu L. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies. Ann Transl Med 2020;8:540. [PMID: 32411763 DOI: 10.21037/atm.2020.02.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, Jiang J, Huang X, Tong H, Tian Y. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7:1670-1679. [PMID: 29573235 DOI: 10.1002/cam4.1390] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
300 Huang Y, Hu L, Huang S, Xu W, Wan J, Wang D, Zheng G, Xia Z. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Int J Nanomedicine 2018;13:8309-23. [PMID: 30584302 DOI: 10.2147/IJN.S184379] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
301 Qian X, Zhang W, Shams A, Mohammed K, Befeler AS, Kang N, Lai J. Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization. Liver Res 2020;4:212-7. [PMID: 33520338 DOI: 10.1016/j.livres.2020.11.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y, Gong C, Han B, He G. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy. Acta Biomaterialia 2018;74:414-29. [DOI: 10.1016/j.actbio.2018.05.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
303 Kamimura K, Suda T, Fukuhara Y, Okuda S, Watanabe Y, Yokoo T, Osaki A, Waguri N, Ishikawa T, Sato T, Aoyagi Y, Takamura M, Wakai T, Terai S. Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers. Sci Rep 2021;11:6255. [PMID: 33737617 DOI: 10.1038/s41598-021-85498-7] [Reference Citation Analysis]
304 Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis 2019;10:333. [PMID: 30988277 DOI: 10.1038/s41419-019-1530-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
305 Zou RC, Li LL, Yuan HL. Current Status of Research on the Role of Circular RNAs in Hepatocellular Carcinoma and Clinical Implications. Med Sci Monit 2020;26:e923832. [PMID: 32779638 DOI: 10.12659/MSM.923832] [Reference Citation Analysis]
306 Du B, Zhang P, Tan Z, Xu J. MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 2017;96:1246-52. [PMID: 29217161 DOI: 10.1016/j.biopha.2017.11.090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
307 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
308 Morise Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. Transl Gastroenterol Hepatol 2018;3:41. [PMID: 30148226 DOI: 10.21037/tgh.2018.07.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
309 Lian YF, Huang YL, Wang JL, Deng MH, Xia TL, Zeng MS, Chen MS, Wang HB, Huang YH. Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma. Aging (Albany NY) 2018;10:1884-901. [PMID: 30103211 DOI: 10.18632/aging.101510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
310 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
311 Chen ZH, Zhang XP, Wang K, Sun JX, Chai ZT, Yang Y, Guo WX, Shi J, Lau WY, Cheng SQ. Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: A propensity score matching analysis. Hepatol Res 2019;49:441-52. [PMID: 30549370 DOI: 10.1111/hepr.13297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
312 Wang XJ, Li FF, Zhang YJ, Jiang M, Ren WH. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis. Cancer Biomark 2020;29:307-15. [PMID: 32716348 DOI: 10.3233/CBM-201577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
313 Pinato DJ. Breaking Kuhn's paradigm in advanced hepatocellular carcinoma. Hepatology 2018;67:1663-5. [DOI: 10.1002/hep.29714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
314 Chen GX, Qi CY, Hu WJ, Wang XH, Hua YP, Kuang M, Peng BG, Li SQ. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma. BMC Cancer 2020;20:487. [PMID: 32471389 DOI: 10.1186/s12885-020-06980-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
316 Lee MH, Thomas JL, Li JA, Chen JR, Wang TL, Lin HY. Synthesis of Multifunctional Nanoparticles for the Combination of Photodynamic Therapy and Immunotherapy. Pharmaceuticals (Basel) 2021;14:508. [PMID: 34073468 DOI: 10.3390/ph14060508] [Reference Citation Analysis]
317 Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Acharya RU, Yeong CH. Neutron-activated biodegradable samarium-153 acetylacetonate-poly-L-lactic acid microspheres for intraarterial radioembolization of hepatic tumors. World J Exp Med 2020; 10(2): 10-25 [PMID: 32266125 DOI: 10.5493/wjem.v10.i2.10] [Reference Citation Analysis]
318 Long GB, Xiao CW, Zhao XY, Zhang J, Li X. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e20745. [PMID: 32590750 DOI: 10.1097/MD.0000000000020745] [Reference Citation Analysis]
319 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
320 Zhen H, Qian X, Fu X, Chen Z, Zhang A, Shi L. Regulation of Shaoyao Ruangan Mixture on Intestinal Flora in Mice With Primary Liver Cancer. Integr Cancer Ther 2019;18:1534735419843178. [PMID: 31006277 DOI: 10.1177/1534735419843178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
321 Wong RJ, Ahmed A; Hepatocellular Carcinoma Research Committee of the Chronic Liver Disease Foundation. Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.J Clin Gastroenterol. 2020;54:850-856. [PMID: 33030855 DOI: 10.1097/MCG.0000000000001422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Wang Y, Shang W, Zhong H, Luo T, Niu M, Xu K, Tian J. Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. ACS Nano 2020;14:14907-18. [PMID: 33111520 DOI: 10.1021/acsnano.0c04341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
323 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 22.7] [Reference Citation Analysis]
324 Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71. [PMID: 28279536 DOI: 10.1016/j.medcli.2016.12.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
325 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
326 Schoenberg MB, Bucher JN, Vater A, Bazhin AV, Hao J, Guba MO, Angele MK, Werner J, Rentsch M. Resection or Transplant in Early Hepatocellular Carcinoma. Dtsch Arztebl Int 2017;114:519-26. [PMID: 28835324 DOI: 10.3238/arztebl.2017.0519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
327 Huang J, Liu FC, Li L, Yuan SX, Yang Y, Jiang BG, Liu H, Pan ZY. Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection. Am J Clin Oncol 2020;43:20-7. [PMID: 31633514 DOI: 10.1097/COC.0000000000000619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
328 Hobeika C, Fuks D, Cauchy F, Goumard C, Soubrane O, Gayet B, Salamé E, Cherqui D, Vibert E, Scatton O, Nomi T, Oudafal N, Kawai T, Komatsu S, Okumura S, Petrucciani N, Laurent A, Bucur P, Barbier L, Trechot B, Nunèz J, Tedeschi M, Allard MA, Golse N, Ciacio O, Pittau G, Cunha AS, Adam R, Laurent C, Chiche L, Leourier P, Rebibo L, Regimbeau JM, Ferre L, Souche FR, Chauvat J, Fabre JM, Jehaes F, Mohkam K, Lesurtel M, Ducerf C, Mabrut JY, Hor T, Paye F, Balladur P, Suc B, Muscari F, Millet G, El Amrani M, Ratajczak C, Lecolle K, Boleslawski E, Truant S, Pruvot FR, Kianmanesh AR, Codjia T, Schwarz L, Girard E, Abba J, Letoublon C, Chirica M, Carmelo A, VanBrugghe C, Cherkaoui Z, Unterteiner X, Memeo R, Pessaux P, Buc E, Lermite E, Barbieux J, Bougard M, Marchese U, Ewald J, Turini O, Thobie A, Menahem B, Mulliri A, Lubrano J, Zemour J, Fagot H, Passot G, Gregoire E, Hardwigsen J, le Treut YP, Patrice D; AFC-LLR-2018 study group. Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. Br J Surg 2020;107:268-77. [PMID: 31916594 DOI: 10.1002/bjs.11406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
329 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Huang YH, Lei HJ, He YJ, Hou MC, Huo TI. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. Am J Clin Oncol. 2019;42:698-704. [PMID: 31335351 DOI: 10.1097/coc.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
331 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
332 Gupta P, Kalra N, Keshava SN, Chaluvashetty SB, Mukund A, Roy-choudhury SH, Baijal SS, Khandelwal A, Ananthashayana VH, R. SN, Kulkarni S, Shetty NS, Gupta A, Gupta S. Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I. Journal of Clinical Interventional Radiology ISVIR 2020;4:098-106. [DOI: 10.1055/s-0040-1715774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
333 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
334 Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol 2017;67:65-71. [PMID: 28192185 DOI: 10.1016/j.jhep.2017.01.033] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
335 Ling CQ, Fan J, Lin HS, Shen F, Xu ZY, Lin LZ, Qin SK, Zhou WP, Zhai XF, Li B, Zhou QH; Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. J Integr Med 2018;16:236-48. [PMID: 29891180 DOI: 10.1016/j.joim.2018.05.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
336 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
337 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
338 Sun JR, Kong CF, Xiao KM, Yang JL, Qu XK, Sun JH. Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma. Front Genet 2020;11:602542. [PMID: 33381151 DOI: 10.3389/fgene.2020.602542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Wang XK, Liao XW, Yang CK, Liu ZQ, Han QF, Zhou X, Zhang LB, Deng T, Gong YZ, Huang JL, Huang R, Han CY, Yu TD, Su H, Ye XP, Peng T, Zhu GZ. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines. J Cell Physiol 2020;235:7003-17. [PMID: 32037547 DOI: 10.1002/jcp.29596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
340 Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72:626-635. [PMID: 28258743 DOI: 10.1016/j.crad.2017.01.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
341 Chai ZT, Zhang XP, Shao M, Ao JY, Chen ZH, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Wu MC, Lau WY, Cheng SQ. Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Ann Transl Med 2021;9:247. [PMID: 33708874 DOI: 10.21037/atm-20-2229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, Kiso S, Kamada Y, Hikita H, Eguchi H, Ogita H, Doki Y, Mori M, Tatsumi T, Takehara T. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget 2018;9:21022-35. [PMID: 29765517 DOI: 10.18632/oncotarget.24781] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
343 Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018; 10(1): 41-50 [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
344 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
345 Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transpl. 2016;22:1136-1142. [PMID: 27082951 DOI: 10.1002/lt.24461] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
346 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
347 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
348 Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
349 Wang E, Liu L, Xia D, Wang W, Bai W, Wang Q, Yuan J, Li X, Zhang L, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G. Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates. J Vasc Interv Radiol 2017;28:956-62. [PMID: 28420555 DOI: 10.1016/j.jvir.2017.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
350 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Ueno A, Masugi Y, Yamazaki K, Kurebayashi Y, Tsujikawa H, Effendi K, Ojima H, Sakamoto M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 2020;70:140-54. [PMID: 31908112 DOI: 10.1111/pin.12895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
352 Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726. [PMID: 27084592 DOI: 10.1016/j.jhep.2016.04.008] [Cited by in Crossref: 612] [Cited by in F6Publishing: 584] [Article Influence: 122.4] [Reference Citation Analysis]
353 Li J, Hao N, Han J, Zhang M, Li X, Yang N. ZKSCAN3 drives tumor metastasis via integrin β4/FAK/AKT mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Cell Int 2020;20:216. [PMID: 32518525 DOI: 10.1186/s12935-020-01307-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
354 Sagir Kahraman A. Radiomics in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1165-8. [PMID: 32844349 DOI: 10.1007/s12029-020-00493-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
355 Giorgio A, Gatti P, Montesarchio L, Merola MG, Amendola F, Calvanese A, Iaquinto G, Fontana M, Ciracì E, Semeraro S, Santoro B, Coppola C, Matteucci P, Giorgio V. Microwave Ablation in Intermediate Hepatocellular Carcinoma in Cirrhosis: An Italian Multicenter Prospective Study. J Clin Transl Hepatol 2018;6:251-7. [PMID: 30271736 DOI: 10.14218/JCTH.2018.00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
356 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
357 Sun L, Li PB, Yao YF, Xiu AY, Peng Z, Bai YH, Gao YJ. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2018; 24(10): 1120-1133 [PMID: 29563756 DOI: 10.3748/wjg.v24.i10.1120] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
358 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
359 Jia J, Che L, Cigliano A, Wang X, Peitta G, Tao J, Zhong S, Ribback S, Evert M, Chen X, Calvisi DF. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. Int J Mol Sci 2020;21:E8467. [PMID: 33187130 DOI: 10.3390/ijms21228467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
360 Hernaez R, El-Serag HB. How we approach it: treatment options for hepatocellular carcinoma. Am J Gastroenterol 2018;113:791-4. [PMID: 29713029 DOI: 10.1038/s41395-018-0008-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
361 Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18:603-10. [PMID: 31067134 DOI: 10.1080/14740338.2019.1617272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
362 Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma. Lancet 2017;389:4-6. [PMID: 27932228 DOI: 10.1016/S0140-6736(16)32480-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
363 Quan Y, Li Z, Zhu K, Liang J. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma. Lipids Health Dis 2021;20:74. [PMID: 34304741 DOI: 10.1186/s12944-021-01486-w] [Reference Citation Analysis]
364 Wang PC, Hu ZQ, Zhou SL, Zhan H, Zhou ZJ, Luo CB, Huang XW. Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis. Future Oncol 2018;14:1177-86. [PMID: 29316827 DOI: 10.2217/fon-2017-0672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
365 Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384-391. [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
366 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
367 Huang T, Guo YZ, Yue X, Zhang GP, Zhang Y, Kuang M, Peng BG, Li SQ. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma. Carcinogenesis 2020;41:571-81. [PMID: 32648918 DOI: 10.1093/carcin/bgz133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 de Campos PB, Oliveira CP, Stefano JT, Martins-Filho SN, Chagas AL, Herman P, D'Albuquerque LC, Alvares-da-Silva MR, Longatto-Filho A, Carrilho FJ, Alves VAF. Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype. Histol Histopathol 2020;35:729-40. [PMID: 31858523 DOI: 10.14670/HH-18-194] [Reference Citation Analysis]
369 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
370 Kobayashi M, Mikami D, Uwada J, Yazawa T, Kamiyama K, Kimura H, Taniguchi T, Iwano M. A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells. Oncotarget 2018;9:31342-54. [PMID: 30140374 DOI: 10.18632/oncotarget.25809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
371 Zhao W, Qiu L, Liu H, Xu Y, Zhan M, Zhang W, Xin Y, He X, Yang X, Bai J, Xiao J, Guan Y, Li Q, Chang L, Yi X, Li Y, Chen X, Lu L. Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer. J Gastrointest Oncol 2020;11:1065-77. [PMID: 33209498 DOI: 10.21037/jgo-20-409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
372 Fukami Y, Saito T, Osawa T, Arikawa T, Matsumura T, Kurahashi S, Komatsu S, Kaneko K, Sano T. Preoperative Controlling Nutritional Status plus Tumor Burden Score for the Assessment of Prognosis after Curative Liver Resection for Hepatocellular Carcinoma. Med Princ Pract 2021;30:131-7. [PMID: 33361696 DOI: 10.1159/000514031] [Reference Citation Analysis]
373 Stocker D, Marquez HP, Wagner MW, Raptis DA, Clavien PA, Boss A, Fischer MA, Wurnig MC. MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver. Heliyon 2018;4:e00987. [PMID: 30761374 DOI: 10.1016/j.heliyon.2018.e00987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
374 Chew SA, Moscato S, George S, Azimi B, Danti S. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers (Basel) 2019;11:E2026. [PMID: 31888198 DOI: 10.3390/cancers11122026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
375 Ho SY, Hsu CY, Liu PH, Hsia CY, Su CW, Huang YH, Hou MC, Huo TI. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2019;45:776-781. [PMID: 30401507 DOI: 10.1016/j.ejso.2018.10.541] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
376 Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018;9:30869-82. [PMID: 30112114 DOI: 10.18632/oncotarget.25766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
377 Li A, Wang Q, He G, Jin J, Huang G. DEP domain containing 1 suppresses apoptosis via inhibition of A20 expression, which activates the nuclear factor κB signaling pathway in HepG2 cells. Oncol Lett 2018;16:949-55. [PMID: 29963168 DOI: 10.3892/ol.2018.8770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
378 Pelizzaro F, Penzo B, Peserico G, Imondi A, Sartori A, Vitale A, Cillo U, Giannini EG, Forgione A, Ludovico Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Giuseppe Foschi F, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Monofocal hepatocellular carcinoma: How much does size matter? Liver Int 2021;41:396-407. [PMID: 33155401 DOI: 10.1111/liv.14718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
380 Tan CK. Peretinoin as an adjuvant therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:1201-10. [PMID: 27649418 DOI: 10.1080/17474124.2016.1238303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
381 Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, Kim JK. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol 2021;216:1566-73. [PMID: 33852336 DOI: 10.2214/AJR.20.23213] [Reference Citation Analysis]
382 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
383 Huang S, Wu Y, Zeng F, Chen J, Wu S. A turn-on fluorescence probe based on aggregation-induced emission for leucine aminopeptidase in living cells and tumor tissue. Analytica Chimica Acta 2018;1031:169-77. [DOI: 10.1016/j.aca.2018.05.032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
384 Meng W, Tai Y, Zhao H, Fu B, Zhang T, Liu W, Li H, Yang Y, Zhang Q, Feng Y, Chen G. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance. Med Sci Monit 2017;23:1295-304. [PMID: 28291769 DOI: 10.12659/msm.902692] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
385 Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, Xu L, Wang K, Chai ZT, Guo WX, Shi J, Xie D, Wu MC, Yee Lau W, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology. 2019;69:2076-2090. [PMID: 30586158 DOI: 10.1002/hep.30490] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
386 Zhong JH, Ma L, Xiang BD, Li LQ, Yang T. We're Still in an Update Process of the BCLC System. Ann Surg 2018;267:e23-4. [PMID: 27455159 DOI: 10.1097/SLA.0000000000001922] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
387 Samie HAA, Saeed M, Faisal SM, Kausar MA, Kamal MA. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. CDM 2019;20:283-91. [DOI: 10.2174/1389200220666190308134351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
388 Kapoor H, Nisiewicz MJ, Jayavarapu R, Gedaly R, Raissi D. Early Outcomes with Single-antenna High-powered Percutaneous Microwave Ablation for Primary and Secondary Hepatic Malignancies: Safety, Effectiveness, and Predictors of Ablative Failure. J Clin Imaging Sci 2020;10:10. [PMID: 32257586 DOI: 10.25259/JCIS_173_2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Eur J Cancer 2020;134:90-8. [PMID: 32497895 DOI: 10.1016/j.ejca.2020.03.032] [Reference Citation Analysis]
390 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
391 Liu S, Yu G, Liu L, Zou X, Zhou L, Hu E, Song Y. Identification of Prognostic Stromal-Immune Score-Based Genes in Hepatocellular Carcinoma Microenvironment. Front Genet 2021;12:625236. [PMID: 33643387 DOI: 10.3389/fgene.2021.625236] [Reference Citation Analysis]
392 Ma XL, Jiang M, Zhao Y, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Cao Y, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2018;25:1686-94. [PMID: 29626309 DOI: 10.1245/s10434-018-6402-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
393 Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M;  Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. Ann Surg. 2020;272:145-154. [PMID: 30672806 DOI: 10.1097/sla.0000000000003192] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 16.0] [Reference Citation Analysis]
394 Zhang XP, Chen ZH, Zhou TF, Li LQ, Chen MS, Wen TF, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ; Chinese National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study. Eur J Surg Oncol 2019;45:1644-51. [PMID: 30982657 DOI: 10.1016/j.ejso.2019.03.043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
395 Zhang Z, Cai M, Bao C, Hu Z, Tian J. Endoscopic Cerenkov luminescence imaging and image-guided tumor resection on hepatocellular carcinoma-bearing mouse models. Nanomedicine. 2019;17:62-70. [PMID: 30654183 DOI: 10.1016/j.nano.2018.12.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
396 Gholam PM, Iyer R, Johnson MS. Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers (Basel) 2019;11:E873. [PMID: 31234476 DOI: 10.3390/cancers11060873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
397 Książek W, Hammad M, Pławiak P, Acharya UR, Tadeusiewicz R. Development of novel ensemble model using stacking learning and evolutionary computation techniques for automated hepatocellular carcinoma detection. Biocybernetics and Biomedical Engineering 2020;40:1512-24. [DOI: 10.1016/j.bbe.2020.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
398 Xu Y, Huang Y, Xu W, Zheng X, Yi X, Huang L, Wang Y, Wu K. Activated Hepatic Stellate Cells (HSCs) Exert Immunosuppressive Effects in Hepatocellular Carcinoma by Producing Complement C3. Onco Targets Ther 2020;13:1497-505. [PMID: 32110047 DOI: 10.2147/OTT.S234920] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
399 Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'unto C, Francioso S, Brega A, Montalbano M, Visco-comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'offizi G, Gasbarrini A, De Santis A, Angelico M. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2018;25:1493-500. [DOI: 10.1111/jvh.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
400 Cunha GM, Kwon H, Wolfson T, Gamst AC, Chung YE, Kim M, Kim SW, Sirlin CB, Fowler KJ. Examining LI-RADS recommendations: should observation size only be measured on non-arterial phases? Abdom Radiol 2020;45:3144-54. [DOI: 10.1007/s00261-020-02490-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
401 Wu J, Niu Q, Yuan J, Xu X, Cao L. Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1. Exp Ther Med 2019;18:4209-20. [PMID: 31777531 DOI: 10.3892/etm.2019.8080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
402 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
403 Pinato DJ, Yen C, Sharma R. Reply to: ‘Validating the ALBI grade: Its current and future use in HCC prognostication’. Journal of Hepatology 2017;66:663-4. [DOI: 10.1016/j.jhep.2016.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Zhao J, Wu C, Zhai L, Shi X, Li X, Weng G, Zhu J, Li J, Zhao J. A SERS-based immunoassay for the detection of α-fetoprotein using AuNS@Ag@SiO 2 core–shell nanostars. J Mater Chem C 2019;7:8432-41. [DOI: 10.1039/c9tc01890e] [Cited by in Crossref: 12] [Article Influence: 6.0] [Reference Citation Analysis]
405 Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, Lai ZC, Xu YJ, Kan A, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:619461. [PMID: 34055599 DOI: 10.3389/fonc.2021.619461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Yi PS, Li Y, Yan S, Wu B, Lan C, Li JS. Surgery combined with post-operative trancatheter arterial chemoembolization improves survival of intermediate hepatocellular carcinoma. Scand J Gastroenterol 2019;54:240-5. [PMID: 30880503 DOI: 10.1080/00365521.2019.1577487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Imajo K, Ogawa Y, Yoneda M, Saito S, Nakajima A. A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma.J Med Ultrason (2001). 2020;47:265-277. [PMID: 31960190 DOI: 10.1007/s10396-019-00997-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 96] [Article Influence: 18.2] [Reference Citation Analysis]
410 Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells. Biomed Pharmacother 2020;125:110033. [PMID: 32187962 DOI: 10.1016/j.biopha.2020.110033] [Reference Citation Analysis]
411 Lim C, Salloum C, Osseis M, Lahat E, Gómez-Gavara C, Compagnon P, Luciani A, Feray C, Azoulay D. Short-term outcomes following hepatectomy for hepatocellular carcinoma within and beyond the BCLC guidelines: A prospective study. HPB (Oxford) 2018;20:222-30. [PMID: 28935451 DOI: 10.1016/j.hpb.2017.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
412 Lee JH, Lee IJ, Kim HB, Park B, Kim BH, Park JW, Kim CM. Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. Clin Radiol 2019;74:407.e19-28. [PMID: 30837076 DOI: 10.1016/j.crad.2019.01.024] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
413 Yin Z, Ma T, Yan J, Shi N, Zhang C, Lu X, Hou B, Jian Z. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway. J Cell Physiol 2019;234:18825-36. [PMID: 30924168 DOI: 10.1002/jcp.28521] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
414 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
415 Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology 2018;155:431-442.e10. [PMID: 29729258 DOI: 10.1053/j.gastro.2018.04.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
416 Ko SE, Lee MW, Rhim H, Kang TW, Song KD, Cha DI, Lim HK. Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma. Int J Hyperthermia 2020;37:1354-61. [PMID: 33297809 DOI: 10.1080/02656736.2020.1849824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Piñero F, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Coronel M, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Rubinstein F, Silva M; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018;30:376-83. [PMID: 29509603 DOI: 10.1097/MEG.0000000000001049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
418 Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS One 2017;12:e0185198. [PMID: 29016627 DOI: 10.1371/journal.pone.0185198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
419 Zhu P, Liang H, Huang X, Zeng Q, Liu Y, Lv J, Ming L. Circular RNA Hsa_circ_0004018 Inhibits Wnt/β-Catenin Signaling Pathway by Targeting microRNA-626/DKK3 in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:9351-64. [PMID: 33061423 DOI: 10.2147/OTT.S254997] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
420 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
421 Fang KC, Su CW, Chiou YY, Lee PC, Chiu NC, Liu CA, Chen PH, Kao WY, Huang YH, Huo TI, Hou MC, Lin HC, Wu JC. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. Eur Radiol. 2017;27:2600-2609. [PMID: 27678133 DOI: 10.1007/s00330-016-4604-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
422 Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018;50:640-646. [PMID: 29636240 DOI: 10.1016/j.dld.2018.03.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
423 Wang XH, Long LH, Cui Y, Jia AY, Zhu XG, Wang HZ, Wang Z, Zhan CM, Wang ZH, Wang WH. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma. Br J Cancer 2020;122:978-85. [PMID: 31937925 DOI: 10.1038/s41416-019-0706-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
424 Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu D, Ding Y. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma. Sci Rep 2017;7:5517. [PMID: 28717245 DOI: 10.1038/s41598-017-04811-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
425 Wang Y, Zhong J, Xu H, Xu G, Wang L, Xu D, Wang H, Wang K, Xiang B, Mao Y, Li L, Xing B. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther 2019;49:202-10. [DOI: 10.1111/apt.15074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
426 Lewis S, Hectors S, Taouli B. Radiomics of hepatocellular carcinoma. Abdom Radiol (NY). 2021;46:111-123. [PMID: 31925492 DOI: 10.1007/s00261-019-02378-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
427 Gorgen A, Rosales R, Sadler E, Beecroft R, Knox J, Dawson LA, Ghanekar A, Grant D, Greig PD, Sapisochin G. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation 2019;103:2136-43. [DOI: 10.1097/tp.0000000000002616] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Mo D, Jia R, Zhong J. Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward. Hepatology 2019;70:446-7. [DOI: 10.1002/hep.30409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
429 Wang L, Ke Q, Lin N, Huang Q, Zeng Y, Liu J. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2019;36:1288-96. [PMID: 31852267 DOI: 10.1080/02656736.2019.1692148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
430 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
431 Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun 2021;42:583-91. [PMID: 33625188 DOI: 10.1097/MNM.0000000000001380] [Reference Citation Analysis]
432 Yi PS, Wu B, Deng DW, Zhang GN, Li JS. Positive expression of ZNF689 indicates poor prognosis of hepatocellular carcinoma. Oncol Lett 2018;16:5122-30. [PMID: 30250580 DOI: 10.3892/ol.2018.9295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
433 Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019;13:199-204. [PMID: 30671808 DOI: 10.1007/s12072-019-09929-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
434 Mo Y, Wu Y, Li X, Rao H, Tian X, Wu D, Qiu Z, Zheng G, Hu J. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation. European Journal of Pharmacology 2020;867:172788. [DOI: 10.1016/j.ejphar.2019.172788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
435 Rodríguez-Hernández MA, de la Cruz-Ojeda P, Gallego P, Navarro-Villarán E, Staňková P, Del Campo JA, Kučera O, Elkalaf M, Maseko TE, Červinková Z, Muntané J. Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochem Pharmacol 2020;176:113902. [PMID: 32156660 DOI: 10.1016/j.bcp.2020.113902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
436 Yang L, Wei C, Li Y, He X, He M. miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers. Biomark Med 2020;14:1485-500. [PMID: 33155836 DOI: 10.2217/bmm-2020-0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
438 Zhu L, Li T, Ma X, Qiu Y, Ma X, Lin Y, Han L, Qin C. A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Sci Rep 2017;7:8954. [PMID: 28827721 DOI: 10.1038/s41598-017-09358-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
439 Yang L, Hu Y, Zhou G, Chen Q, Song Z. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways. Biosci Rep 2020;40:BSR20193137. [PMID: 32677672 DOI: 10.1042/BSR20193137] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
440 Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, Guo RP. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:618206. [PMID: 33718175 DOI: 10.3389/fonc.2021.618206] [Reference Citation Analysis]
441 Jiang Z, Wang S, Hou J, Chi J, Wang S, Shao K, Liu W, Sun R, Han B. Effects of carboxymethyl chitosan oligosaccharide on regulating immunologic function and inhibiting tumor growth. Carbohydr Polym 2020;250:116994. [PMID: 33049904 DOI: 10.1016/j.carbpol.2020.116994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
442 Drucker E, Holzer K, Pusch S, Winkler J, Calvisi DF, Eiteneuer E, Herpel E, Goeppert B, Roessler S, Ori A, Schirmacher P, Breuhahn K, Singer S. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell Commun Signal 2019;17:159. [PMID: 31783876 DOI: 10.1186/s12964-019-0456-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
443 Fan W, Yuan G, Fan H, Li F, Wu Y, Zhao Y, Yao W, Wang Y, Xue M, Yang J, Li J. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clin Ther 2019;41:1463-76. [PMID: 31303279 DOI: 10.1016/j.clinthera.2019.04.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
444 Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, Zhu H, Shui P. The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Front Oncol 2020;10:570465. [PMID: 33575207 DOI: 10.3389/fonc.2020.570465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
445 Okamoto Y, Hasebe T, Bito K, Yano K, Matsumoto T, Tomita K, Hotta A. Fabrication of radiopaque drug-eluting beads based on Lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma. Polymer Degradation and Stability 2020;175:109106. [DOI: 10.1016/j.polymdegradstab.2020.109106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
446 Berzigotti A, França M, Martí-aguado D, Martí-bonmatí L. Cuantificación de la fibrosis hepática mediante biomarcadores de imagen. Radiología 2018;60:74-84. [DOI: 10.1016/j.rx.2017.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
447 Zhang Q, Xing W, Zhang J, Hu J, Qi L, Xiang B. Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma. Onco Targets Ther 2021;14:1543-52. [PMID: 33688202 DOI: 10.2147/OTT.S298576] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
448 Bu LJ, Yu HQ, Fan LL, Li XQ, Wang F, Liu JT, Zhong F, Zhang CJ, Wei W, Wang H, Sun GP. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation. World J Gastroenterol 2017; 23(6): 986-998 [PMID: 28246472 DOI: 10.3748/wjg.v23.i6.986] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
449 Li Z, Hu Y, Wang H, Wang M, Gu X, Ping Y, Zeng Q, Li H, Yan J, Yu Z. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. Eur J Gastroenterol Hepatol 2020;32:447-53. [PMID: 32012142 DOI: 10.1097/MEG.0000000000001631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
450 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
451 Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, Kulik L, Ganger D, Desai K, Thornburg B. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018;287:1050-1058. [PMID: 29688155 DOI: 10.1148/radiol.2018171768] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 24.3] [Reference Citation Analysis]
452 Wei LH, Dong Y, Sun YF, Mei XS, Ma XS, Shi J, Yang QL, Ji YR, Zhang ZH, Sun HN, Sun XR, Song SM. Anticancer property of Hemp Bioactive Peptides in Hep3B liver cancer cells through Akt/GSK3β/β-catenin signaling pathway. Food Sci Nutr 2021;9:1833-41. [PMID: 33841802 DOI: 10.1002/fsn3.1976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Shuai T, Zhou Y, Shao G, Yang R, Wang L, Wang J, Sun J, Ren L, Wang J, Liao Y, Wei M, Xu Q, Li Y, Zhao L. Bimodal Molecule as NIR-CT Contrast Agent for Hepatoma Specific Imaging. Anal Chem 2020;92:1138-46. [PMID: 31820637 DOI: 10.1021/acs.analchem.9b04212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Wörns MA, Galle PR. Hepatocellular carcinoma in 2017: Two large steps forward, one small step back. Nat Rev Gastroenterol Hepatol 2018;15:74-6. [PMID: 29300046 DOI: 10.1038/nrgastro.2017.174] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
455 Yu M, Li Z. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. Front Med 2017;11:509-21. [DOI: 10.1007/s11684-017-0546-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
456 Li C, Wu M, Zong G, Wan C, Liu Q, Zhou H, Hua L, Chen Y, Chen X, Lu C. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci 2017;62:133-42. [PMID: 27921263 DOI: 10.1007/s10620-016-4365-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
457 Wu X, Wang H, Lian Y, Chen L, Gu L, Wang J, Huang Y, Deng M, Gao Z, Huang Y. GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis. Sci Rep 2017;7:5129. [PMID: 28698581 DOI: 10.1038/s41598-017-05311-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
458 Zhuang BW, Li W, Xie XH, Hu HT, Lu MD, Xie XY. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Jpn J Clin Oncol 2019;49:845-55. [PMID: 31063184 DOI: 10.1093/jjco/hyz069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
459 Mohkam K, Rode A, Darnis B, Manichon A, Boussel L, Ducerf C, Merle P, Lesurtel M, Mabrut J. Hepatic venous pressure gradient after portal vein embolization: An accurate predictor of future liver remnant hypertrophy. Surgery 2018;164:227-32. [DOI: 10.1016/j.surg.2018.03.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
460 Liu W, Hu J, Zhou K, Chen F, Wang Z, Liao B, Dai Z, Cao Y, Fan J, Zhou J. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. Onco Targets Ther. 2017;10:3843-3851. [PMID: 28814883 DOI: 10.2147/ott.s140062] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 17.5] [Reference Citation Analysis]
461 Chagas AL, Felga GEG, Diniz MA, Silva RF, Mattos AA, Silva RCMA, Boin IFSF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019;31:1148-56. [PMID: 31247632 DOI: 10.1097/MEG.0000000000001448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
462 Bruix J, Ayuso C. Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty. Gastroenterology 2019;156:860-2. [PMID: 30776351 DOI: 10.1053/j.gastro.2019.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
463 Yao BR, Sun Y, Chen SL, Suo HD, Zhang YL, Wei H, Wang CH, Zhao F, Cong W, Xin WY, Hou GG. Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation. Eur J Med Chem 2019;167:187-99. [PMID: 30771605 DOI: 10.1016/j.ejmech.2019.02.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 13.5] [Reference Citation Analysis]
464 Walcott-Sapp S, Billingsley KG. Preoperative optimization for major hepatic resection. Langenbecks Arch Surg 2018;403:23-35. [PMID: 29150719 DOI: 10.1007/s00423-017-1638-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
465 Grazioli L, Faletti R, Frittoli B, Battisti G, Ambrosini R, Romanini L, Gatti M, Fonio P. Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study. Radiol med 2018;123:910-7. [DOI: 10.1007/s11547-018-0927-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
466 Lou X, Li J, Yu D, Wei YQ, Feng S, Sun JJ. Comprehensive analysis of five long noncoding RNAs expression as competing endogenous RNAs in regulating hepatoma carcinoma. Cancer Med 2019;8:5735-49. [PMID: 31392826 DOI: 10.1002/cam4.2468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
467 Sulaiman SA, Abu N, Ab-Mutalib NS, Low TY, Jamal R. Signatures of gene expression, DNA methylation and microRNAs of hepatocellular carcinoma with vascular invasion. Future Oncol 2019;15:2603-17. [PMID: 31339048 DOI: 10.2217/fon-2018-0909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
468 Elsayed M, Ermentrout RM, Sethi I, Bercu ZL, Galt JR, Whitmore M, Brandon DC, Schuster DM, Kokabi N. Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center. Clin Nucl Med 2020;45:100-4. [PMID: 31876805 DOI: 10.1097/RLU.0000000000002828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
469 Xiao Y, Najeeb RM, Ma D, Yang K, Zhong Q, Liu Q. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res 2019;38:458. [PMID: 31703591 DOI: 10.1186/s13046-019-1444-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
470 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
471 Mohkam K, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J Hepatol 2018;68:1172-80. [PMID: 29410287 DOI: 10.1016/j.jhep.2018.01.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
472 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
474 Thaiss W, Kaufmann S, Kloth C, Nikolaou K, Bösmüller H, Horger M. VEGFR-2 expression in HCC, dysplastic and regenerative liver nodules, and correlation with pre-biopsy Dynamic Contrast Enhanced CT. European Journal of Radiology 2016;85:2036-41. [DOI: 10.1016/j.ejrad.2016.09.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
475 Dong X, Wang F, Liu C, Ling J, Jia X, Shen F, Yang N, Zhu S, Zhong L, Li Q. Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma. Cell Death Discov 2021;7:14. [PMID: 33462196 DOI: 10.1038/s41420-021-00403-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Luo J, Si Z, Li T, Li J, Zhang Z, Chen G, Qi H, Yao H. MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway. American Journal of Physiology-Cell Physiology 2019;316:C299-311. [DOI: 10.1152/ajpcell.00189.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
477 Wu S, Chen X, Hu C, Wang J, Shen Y, Zhong Z. Up-Regulated Maternal Embryonic Leucine Zipper Kinase Predicts Poor Prognosis of Hepatocellular Carcinoma Patients in a Chinese Han Population. Med Sci Monit 2017;23:5705-13. [PMID: 29192136 DOI: 10.12659/msm.907600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
478 Conde de la Rosa L, Garcia-Ruiz C, Vallejo C, Baulies A, Nuñez S, Monte MJ, Marin JJG, Baila-Rueda L, Cenarro A, Civeira F, Fuster J, Garcia-Valdecasas JC, Ferrer J, Karin M, Ribas V, Fernandez-Checa JC. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. J Hepatol 2021;74:1429-41. [PMID: 33515644 DOI: 10.1016/j.jhep.2021.01.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
479 Mai RY, Ye JZ, Long ZR, Shi XM, Bai T, Chen J, Li LQ, Wu GB, Wu FX. Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma. Cancer Manag Res. 2019;11:1401-1414. [PMID: 30863151 DOI: 10.2147/cmar.s186114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
480 Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 2018;101:72-81. [PMID: 29571804 DOI: 10.1016/j.ejrad.2018.01.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 26.7] [Reference Citation Analysis]
481 Yong CC, Elsarawy AM, Wang SH, Lin TS, Wang CC, Li WF, Lin TL, Kuo FY, Cheng YF, Chen CL, Lin CC. The surgical challenges of salvage living donor liver transplantation for Hepatocellular carcinoma; The cumulative experience of 100 cases - A retrospective cohort study and a propensity score analysis. Int J Surg 2018;54:187-92. [PMID: 29723674 DOI: 10.1016/j.ijsu.2018.04.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
482 Hui T, Chuah T, Low H, Tan C. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clinical Radiology 2018;73:1056.e11-6. [DOI: 10.1016/j.crad.2018.07.109] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
483 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
484 Wang M, Xi D, Ning Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int. 2017;11:171-180. [PMID: 28097530 DOI: 10.1007/s12072-016-9779-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
485 Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
486 Yi PS, Wang H, Li JS. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(3): 85-92 [PMID: 32218891 DOI: 10.4240/wjgs.v12.i3.85] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
487 Zhang J, Liu X, Zhang H, He X, Liu Y, Zhou J, Guo D. Texture Analysis Based on Preoperative Magnetic Resonance Imaging (MRI) and Conventional MRI Features for Predicting the Early Recurrence of Single Hepatocellular Carcinoma after Hepatectomy. Academic Radiology 2019;26:1164-73. [DOI: 10.1016/j.acra.2018.10.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
488 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
489 Zhou Y, Jing X, Zhang X, Ding J, Wang Y, Zhou H, Zhang Q, Chen Y, Yue W. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis. Ultrasound in Medicine & Biology 2019;45:693-701. [DOI: 10.1016/j.ultrasmedbio.2018.10.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
490 Magalhães J, Monteiro S, Xavier S, Leite S, de Castro FD, Cotter J. Endoscopic ultrasonography - emerging applications in hepatology. World J Gastrointest Endosc 2017; 9(8): 378-388 [PMID: 28874958 DOI: 10.4253/wjge.v9.i8.378] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
491 Li L, Xie R, Lu G. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20210760. [PMID: 34027555 DOI: 10.1042/BSR20210760] [Reference Citation Analysis]
492 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
493 Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? Med Sci Monit 2019;25:4941-51. [PMID: 31270311 DOI: 10.12659/MSM.916451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
494 Pan Q, Qin F, Yuan H, He B, Yang N, Zhang Y, Ren H, Zeng Y. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma. Cancer Med 2021;10:3139-52. [PMID: 33818013 DOI: 10.1002/cam4.3890] [Reference Citation Analysis]
495 Shin N, Han EC, Won S, Ryoo SB, Choe EK, Park BK, Park KJ. The prognoses and postoperative outcomes of patients with both colorectal cancer and liver cirrhosis based on a nationwide cohort in Korea. Ann Surg Treat Res 2020;99:82-9. [PMID: 32802813 DOI: 10.4174/astr.2020.99.2.82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
496 Hanazawa T, Fukami Y, Osawa T, Kurahashi S, Matsumura T, Saito T, Komatsu S, Kaneko K, Tsuzuki T, Sano T. A case of resected hepatocellular carcinoma with gallbladder metastasis. Surg Case Rep 2021;7:145. [PMID: 34138407 DOI: 10.1186/s40792-021-01222-7] [Reference Citation Analysis]
497 Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, Wang W, Kubota Y, Goto T, Komiyama Y, Higuchi M, Takaura K, Hayashi T, Takada H, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Himeno Y, Izumi N. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442-50. [PMID: 29278654 DOI: 10.1111/hepr.13048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
498 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
499 Chen Q, Sun D, Pei H, Su B, Bao K, Cao H, Zhang C, Hammock BD, Liu X. Development of a nanobody tagged with streptavidin-binding peptide and its application in a Luminex fluoroimmunoassay for alpha fetal protein in serum. RSC Adv 2020;10:23767-74. [DOI: 10.1039/d0ra04210b] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
500 Jin C, Zhang XY, Li JW, Li C, Peng W, Wen TF, Luo Y, Lu Q, Zhong XF, Zhang JY, Yan LN, Yang JY. Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy? Oncotarget 2017;8:83698-711. [PMID: 29137375 DOI: 10.18632/oncotarget.19624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
501 Chen H, Zhou B, Yang J, Ma X, Deng S, Huang Y, Wen Y, Yuan J, Yang X. Essential Oil Derived From Eupatorium adenophorum Spreng. Mediates Anticancer Effect by Inhibiting STAT3 and AKT Activation to Induce Apoptosis in Hepatocellular Carcinoma. Front Pharmacol 2018;9:483. [PMID: 29867489 DOI: 10.3389/fphar.2018.00483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
502 An P, Xu J, Yu Y, Winkler CA. Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma. Front Genet 2018;9:261. [PMID: 30073017 DOI: 10.3389/fgene.2018.00261] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
503 Guarino M, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone Megna A, Izzo F, Nardone G, Piai G, Adinolfi LE. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. J Gastroenterol Hepatol. 2018;33:1123-1130. [PMID: 28994145 DOI: 10.1111/jgh.14013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
504 Liu Y, Zhang Y, Zhang T. Long Non-Coding RNA MACC1-AS1 Is Involved in Distant Recurrence of Hepatocellular Carcinoma After Surgical Resection. Med Sci Monit 2020;26:e921175. [PMID: 32267834 DOI: 10.12659/MSM.921175] [Reference Citation Analysis]
505 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
506 Shirata C, Kaneko J, Inagaki Y, Kokudo T, Sato M, Kiritani S, Akamatsu N, Arita J, Sakamoto Y, Hasegawa K. Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress. Sci Rep. 2017;7:13958. [PMID: 29066756 DOI: 10.1038/s41598-017-14401-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 17.5] [Reference Citation Analysis]
507 Chang CY, Wei CY, Chen PH, Hou MC, Chao Y, Chau GY, Lee RC, Huang YH, Su YH, Wu JC, Su CW. The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. J Chin Med Assoc 2021;84:136-43. [PMID: 33433133 DOI: 10.1097/JCMA.0000000000000482] [Reference Citation Analysis]
508 Pellerin O, Amara I, Sapoval M, Méachi T, Déan C, Beaune P, de Waziers I. Hepatic Intra-arterial Delivery of a "Trojan-horses" Gene Therapy: A Pilot Study on Rabbit VX2 Hepatic Tumor Model. Cardiovasc Intervent Radiol 2018;41:153-62. [PMID: 29090347 DOI: 10.1007/s00270-017-1833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
509 Cai W, Fan Y, Hu H, Xiang N, Fang C, Jia F. Postoperative liver volume was accurately predicted by a medical image three dimensional visualization system in hepatectomy for liver cancer. Surg Oncol. 2017;26:188-194. [PMID: 28577725 DOI: 10.1016/j.suronc.2017.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
510 El-Melegy MG, Eltaher HM, Gaballah A, El-Kamel AH. Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal. Eur J Pharm Biopharm 2021;168:166-83. [PMID: 34481049 DOI: 10.1016/j.ejpb.2021.08.020] [Reference Citation Analysis]
511 Xu LX, He MH, Dai ZH, Yu J, Wang JG, Li XC, Jiang BB, Ke ZF, Su TH, Peng ZW, Guo Y, Chen ZB, Chen SL, Peng S, Kuang M. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019;. [PMID: 30916311 DOI: 10.1093/annonc/mdz103] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
512 Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. Journal of Hepatology 2018;69:336-44. [DOI: 10.1016/j.jhep.2018.02.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
513 Kobayashi K, Kawaguchi Y, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N. Parenchyma-sparing liver resection for hepatocellular carcinoma in left lateral section is associated with better liver volume recovery. HPB (Oxford) 2018;20:949-55. [PMID: 30007534 DOI: 10.1016/j.hpb.2018.03.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
514 Wang H, Wang R, Huang D, Li S, Gao B, Kang Z, Tang B, Xie J, Yan F, Liang R, Li H, Yan J. Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway. Front Pharmacol 2021;12:592071. [PMID: 33716735 DOI: 10.3389/fphar.2021.592071] [Reference Citation Analysis]
515 Sang W, Chan SL, Chan AW. Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients". Eur J Cancer 2016;68:203-5. [PMID: 27720569 DOI: 10.1016/j.ejca.2016.08.023] [Reference Citation Analysis]
516 López-Grueso MJ, González R, Muntané J, Bárcena JA, Padilla CA. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. Antioxidants (Basel) 2019;8:E501. [PMID: 31652503 DOI: 10.3390/antiox8100501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
517 Ferrasi AC, Fernandez GJ, Grotto RMT, Silva GF, Goncalves J, Costa MC, Enguita FJ, Pardini MIMC. New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma. Sci Rep 2020;10:9886. [PMID: 32555359 DOI: 10.1038/s41598-020-66881-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
518 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer 2017;6:227-35. [PMID: 28626733 DOI: 10.1159/000475777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
519 Zhang TQ, Huang ZM, Shen JX, Chen GQ, Shen LJ, Ai F, Gu YK, Yao W, Zhang YY, Guo RP, Chen MS, Huang JH. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. Therap Adv Gastroenterol 2019;12:1756284819862966. [PMID: 31489030 DOI: 10.1177/1756284819862966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
520 Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
521 Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, Zhu X, Xing BC. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. HPB (Oxford) 2019;21:425-33. [PMID: 30249510 DOI: 10.1016/j.hpb.2018.08.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
522 Liu K, Huang G, Chang P, Zhang W, Li T, Dai Z, Lv Y. Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients. Sci Rep 2020;10:21376. [PMID: 33288828 DOI: 10.1038/s41598-020-78545-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
523 Meng XY, Zhang XP, Sun Z, Wang HQ, Yu WF. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. BMC Anesthesiol 2020;20:233. [PMID: 32928121 DOI: 10.1186/s12871-020-01111-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
524 Otto G, Pitton MB, Hoppe-Lotichius M, Weinmann A. Liver transplantation and BCLC classification: Limitations impede optimum treatment. Hepatobiliary Pancreat Dis Int 2021;20:6-12. [PMID: 33349607 DOI: 10.1016/j.hbpd.2020.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
525 Li SS, Chen DM, Chen LB, Wei H, Wang JL, Xiao J, Huang YH, Lian YF. GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcin oma cells. Mol Med Rep 2021;23:454. [PMID: 33880590 DOI: 10.3892/mmr.2021.12093] [Reference Citation Analysis]
526 Xu W, Rao Q, An Y, Li M, Xu G, Sang X, Lu X, Zhang Z, Mao Y. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China. Medicine (Baltimore). 2018;97:e11800. [PMID: 30095644 DOI: 10.1097/md.0000000000011800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
527 Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66:412-423. [PMID: 27677712 DOI: 10.1016/j.jhep.2016.09.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
528 Xu J, An P, Winkler CA, Yu Y. Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets. Front Oncol. 2020;10:1271. [PMID: 32850386 DOI: 10.3389/fonc.2020.01271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
529 Kim DY. [New Systemic Therapies for Advanced Hepatocellular Carcinoma]. Korean J Gastroenterol. 2019;73:10-15. [PMID: 30690953 DOI: 10.4166/kjg.2019.73.1.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
530 Abreu P, Ivanics T, Jiang K, Chen K, E Hansen B, Sapisochin G, Ghanekar A. Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. HPB (Oxford) 2021;23:359-66. [PMID: 32800449 DOI: 10.1016/j.hpb.2020.07.003] [Reference Citation Analysis]
531 Elshaarawy O, Aman A, Zakaria HM, Zakareya T, Gomaa A, Elshimi E, Abdelsameea E. Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis. World J Gastrointest Oncol 2021; 13(5): 424-439 [PMID: 34040703 DOI: 10.4251/wjgo.v13.i5.424] [Reference Citation Analysis]
532 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
533 Mao K, Yan Y, Zhang J, Wang J, Wang R, Ling X, Liu Y, Lau WY, Jiang S, Liu J, Xiao Z. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: A propensity score matching study. Cancer Med 2018;7:4475-84. [PMID: 30117307 DOI: 10.1002/cam4.1738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
534 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Lurje G, Bednarsch J, Czigany Z, Amygdalos I, Meister F, Schöning W, Ulmer TF, Foerster M, Dejong C, Neumann UP. Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent. Langenbecks Arch Surg 2018;403:851-61. [DOI: 10.1007/s00423-018-1715-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
536 Zhang GC, Liu J, Yu XN, Deng Y, Sun Y, Liu TT, Dong L, Zhu CF, Shen XZ, Zhu JM, Weng SQ, Li Y. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. Adv Healthc Mater 2020;9:e2000650. [PMID: 33000919 DOI: 10.1002/adhm.202000650] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
537 An C, Kim MJ. Imaging features related with prognosis of hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:509-16. [PMID: 30171295 DOI: 10.1007/s00261-018-1758-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
538 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [DOI: 10.3748/wjg.v27.i43.7462] [Reference Citation Analysis]
539 Olya M, Zaferani Arani H, Shekarriz A, Zabolian A, Zare Marzouni H, Aryan H, Hoseinian M, Javidi MA, Atashi HA. Hypericin Exerts Detrimental Effect on Huh-7 As a Delegacy of Hepatocellular Carcinoma: A P53 Dependent Pathway. Galen Med J 2020;9:e1896. [PMID: 34466606 DOI: 10.31661/gmj.v9i0.1896] [Reference Citation Analysis]
540 Meßner M, Schmitt S, Ardelt MA, Fröhlich T, Müller M, Pein H, Huber-Cantonati P, Ortler C, Koenig LM, Zobel L, Koeberle A, Arnold GJ, Rothenfußer S, Kiemer AK, Gerbes AL, Zischka H, Vollmar AM, Pachmayr J. Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma. FASEB J 2020;34:11860-82. [PMID: 32652772 DOI: 10.1096/fj.202001128R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
541 Xu HW, Liu F, Li HY, Wei YG, Li B. Outcomes following laparoscopic versus open major hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score-matched analysis. Surg Endosc. 2018;32:712-719. [PMID: 28726140 DOI: 10.1007/s00464-017-5727-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
542 Xiao F, Li H, Feng Z, Huang L, Kong L, Li M, Wang D, Liu F, Zhu Z, Wei Y, Zhang W. Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade. Sci Rep 2021;11:488. [PMID: 33436794 DOI: 10.1038/s41598-020-80066-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Preziosi M, Monga SP. Novel Genetic Activation Screening in Liver Repopulation and Cancer: Now CRISPR Than Ever! Hepatology 2018;68:408-11. [PMID: 29742805 DOI: 10.1002/hep.30084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Ray PP, Amaral JF, Hinoul P. Innovation Best Practices in the Medical Device Industry. Tech Vasc Interv Radiol 2017;20:90-3. [PMID: 28673652 DOI: 10.1053/j.tvir.2017.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
545 Bu Y, Liu F, Jia QA, Yu SN. Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0165681. [PMID: 27814372 DOI: 10.1371/journal.pone.0165681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
546 Mai RY, Zeng J, Meng WD, Lu HZ, Liang R, Lin Y, Wu GB, Li LQ, Ma L, Ye JZ, Bai T. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. BMC Cancer 2021;21:283. [PMID: 33726693 DOI: 10.1186/s12885-021-07969-4] [Reference Citation Analysis]
547 Zhang W, Zhangyuan G, Wang F, Zhang H, Yu D, Wang J, Jin K, Yu W, Liu Y, Sun B. High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. J Cancer 2019;10:3494-500. [PMID: 31293654 DOI: 10.7150/jca.29499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
548 Ji B, Cai H, Yang Y, Peng F, Song M, Sun K, Yan F, Liu Y. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomaterialia 2020;111:363-72. [DOI: 10.1016/j.actbio.2020.04.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
549 Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr 2016;5:422-8. [PMID: 27826557 DOI: 10.21037/hbsn.2016.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
550 Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:424-432. [PMID: 29631810 DOI: 10.1016/s2468-1253(18)30078-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 25.0] [Reference Citation Analysis]
551 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Reference Citation Analysis]
552 Zhao J, Chen G, Li J, Liu S, Jin Q, Zhang Z, Qi F, Zhang J, Xu J. Loss of PR55α promotes proliferation and metastasis by activating MAPK/AKT signaling in hepatocellular carcinoma. Cancer Cell Int 2021;21:107. [PMID: 33588847 DOI: 10.1186/s12935-021-01796-0] [Reference Citation Analysis]
553 John BV, Aubuchon S, Dahman B, Konjeti VR, Heuman D, Hubert J, Thomas S, Deng Y, Solomon C, Sundaram LT, Love E, Singal AG, Tatum JL. Addition of [18 F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma. Liver Transpl 2020;26:774-84. [PMID: 32128966 DOI: 10.1002/lt.25743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
554 Chen Q, Chen J, He M, Bai Y, Yan H, Zeng N, Liu F, Wen S, Song L, Sheng Z, Liu C, Fang C. Novel small molecular dye-loaded lipid nanoparticles with efficient near-infrared-II absorption for photoacoustic imaging and photothermal therapy of hepatocellular carcinoma. Biomater Sci 2019;7:3165-77. [DOI: 10.1039/c9bm00528e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
555 Zhang XP, Wei XB, Chen ZH, Cheng SQ. Comment on "The Virtual Hepatectomy Changed the Practice of Liver Surgery: More Details, More Significance".Ann Surg. 2019;270:e32-e33. [PMID: 30113333 DOI: 10.1097/SLA.0000000000003007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
556 Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [DOI: 10.1002/hep.31187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
557 Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69:525-33. [PMID: 29653122 DOI: 10.1016/j.jhep.2018.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
558 Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology 2017;284:877-86. [PMID: 28453431 DOI: 10.1148/radiol.2017161413] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
559 Chen K, Li Q, Zhao X, Zhang J, Ma H, Sun X, Yu Q, Zhang Y, Fang C, Nie L. Biocompatible melanin based theranostic agent for in vivo detection and ablation of orthotopic micro-hepatocellular carcinoma. Biomater Sci 2020;8:4322-33. [PMID: 32602480 DOI: 10.1039/d0bm00825g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
560 Green BL, House MG. Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors. Surg Oncol Clin N Am 2019;28:573-86. [PMID: 31472906 DOI: 10.1016/j.soc.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
561 Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC). Med Sci Monit 2018;24:2735-43. [PMID: 29720580 DOI: 10.12659/MSM.907514] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
562 Liu K, Duan J, Liu H, Yang X, Yang J, Wu M, Chang Y. Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. Sci Rep 2019;9:2220. [PMID: 30778112 DOI: 10.1038/s41598-019-39440-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Hainaut P, Amadou A, Gormally E. Cancer prevention and control: hepatocellular carcinoma. Ecancermedicalscience 2019;13:949. [PMID: 31552122 DOI: 10.3332/ecancer.2019.949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
564 Qi X, Yang M, Ma L, Sauer M, Avella D, Kaifi JT, Bryan J, Cheng K, Staveley-O'Carroll KF, Kimchi ET, Li G. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. J Immunother Cancer 2020;8:e001038. [PMID: 33115942 DOI: 10.1136/jitc-2020-001038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
565 Wang Z, Pan L, Guo D, Luo X, Tang J, Yang W, Zhang Y, Luo A, Gu Y, Pan Y. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma. Cancer Med 2021;10:3808-21. [PMID: 33934539 DOI: 10.1002/cam4.3900] [Reference Citation Analysis]
566 Zhu Y, Gao W, Guo Z, Zhou Y, Zhou Y. Liver tissue classification of en face images by fractal dimension-based support vector machine. J Biophotonics 2020;13:e201960154. [PMID: 31909553 DOI: 10.1002/jbio.201960154] [Reference Citation Analysis]
567 Wang Z, Han YJ, Huang S, Wang M, Zhou WL, Li HS, Wang QS, Wu HB. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids 2018;50:309-20. [PMID: 29204748 DOI: 10.1007/s00726-017-2517-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
568 徐峰, 于莹, 杨永红, 刘华, 王娟. IL-28B在乙型肝炎相关性肝癌中的表达及其临床意义. 世界华人消化杂志 2016; 24(12): 1812-1818 [DOI: 10.11569/wcjd.v24.i12.1812] [Reference Citation Analysis]
569 Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Reference Citation Analysis]
570 Fernández-Varo G, Perramón M, Carvajal S, Oró D, Casals E, Boix L, Oller L, Macías-Muñoz L, Marfà S, Casals G, Morales-Ruiz M, Casado P, Cutillas PR, Bruix J, Navasa M, Fuster J, Garcia-Valdecasas JC, Pavel MC, Puntes V, Jiménez W. Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology 2020;72:1267-82. [PMID: 31961955 DOI: 10.1002/hep.31139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
571 Chang Y, Liu Q, Zhou Z, Ding Y, Yang M, Xu W, Chen K, Zhang Q, Wang Z, Li H. Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis. Technol Cancer Res Treat 2020;19:1533033820934881. [PMID: 32552476 DOI: 10.1177/1533033820934881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Jin Y, Wang K, Tian J. Preoperative Examination and Intraoperative Identification of Hepatocellular Carcinoma Using a Targeted Bimodal Imaging Probe. Bioconjugate Chem 2018;29:1475-84. [DOI: 10.1021/acs.bioconjchem.8b00161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
573 Abouzied MM, Fathala A, AlMuhaideb A, Almanea H, Al-Sugair AS, AlSkaff R, Al-Qahtani MH. Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. Radiol Case Rep 2021;16:550-4. [PMID: 33384755 DOI: 10.1016/j.radcr.2020.12.047] [Reference Citation Analysis]
574 Borzio M, Dionigi E, Rossini A, Marignani M, Sacco R, De Sio I, Bertolini E, Francica G, Giacomin A, Parisi G, Vicari S, Toldi A, Salmi A, Boccia S, Mitra M, Fornari F. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology. 2018;67:2215-2225. [PMID: 29165831 DOI: 10.1002/hep.29662] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
575 Dai Z, Wang Z, Lei K, Liao J, Peng Z, Lin M, Liang P, Yu J, Peng S, Chen S, Kuang M. Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Lett 2021;503:1-10. [PMID: 33444692 DOI: 10.1016/j.canlet.2021.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
576 van der Pol J, de Vos-Geelen J, Bucerius J, Mitea C, van der Leij C. Uncomplicated 90Y Selective Internal Radio Therapy in a Patient With Hepatocellular Carcinoma After Arterial and Portal Vein Embolizations. Clin Nucl Med 2018;43:180-2. [PMID: 29389772 DOI: 10.1097/RLU.0000000000001945] [Reference Citation Analysis]
577 Li TE, Zhang Z, Wang Y, Xu D, Dong J, Zhu Y, Wang Z. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:2866-76. [PMID: 33854587 DOI: 10.7150/jca.54408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
578 Kang YS, Jeong EJ, Seok HJ, Kim SK, Hwang JS, Choi ML, Jo DG, Kim Y, Choi J, Lee YJ, Jung E, Min JK, Han TS, Kim JS. Cks1 regulates human hepatocellular carcinoma cell progression through osteopontin expression. Biochem Biophys Res Commun 2019;508:275-81. [PMID: 30497779 DOI: 10.1016/j.bbrc.2018.11.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
579 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
580 Zheng W, Yao M, Qian Q, Sai W, Qiu L, Yang J, Wu W, Dong Z, Yao D. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget 2017;8:52321-32. [PMID: 28881732 DOI: 10.18632/oncotarget.13674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
581 Ismail N, Abdel–mottaleb Y, Eissa Ahmed AA, El-maraghy NN. Novel combination of thymoquinone and resveratrol enhances anticancer effect on hepatocellular carcinoma cell line. Future Journal of Pharmaceutical Sciences 2018;4:41-6. [DOI: 10.1016/j.fjps.2017.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
582 Kunadirek P, Chuaypen N, Jenjaroenpun P, Wongsurawat T, Pinjaroen N, Sirichindakul P, Nookaew I, Tangkijvanich P. Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand. Cancers (Basel) 2021;13:2229. [PMID: 34066484 DOI: 10.3390/cancers13092229] [Reference Citation Analysis]
583 Navarro-Villarán E, Tinoco J, Jiménez G, Pereira S, Wang J, Aliseda S, Rodríguez-Hernández MA, González R, Marín-Gómez LM, Gómez-Bravo MA, Padillo FJ, Álamo-Martínez JM, Muntané J. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLoS One 2016;11:e0160979. [PMID: 27518575 DOI: 10.1371/journal.pone.0160979] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
584 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 25.0] [Reference Citation Analysis]
585 Qiu J, Tang W, Du C. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review. Curr Cancer Drug Targets 2020;20:720-7. [PMID: 32433005 DOI: 10.2174/1568009620666200520084415] [Reference Citation Analysis]
586 Gao J, Dai C, Yu X, Yin XB, Zhou F. Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein. FASEB J 2020;34:5800-17. [PMID: 32128906 DOI: 10.1096/fj.201902705RR] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
587 Chen ZH, Ni QZ, Zhang XP, Ma N, Feng JK, Wang K, Li JJ, Xie D, Ma XY, Cheng SQ. NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. Aging (Albany NY) 2021;13:10672-87. [PMID: 33839702 DOI: 10.18632/aging.202845] [Reference Citation Analysis]
588 Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S, Akarca US; Early Access Program (EAP) Study Groupa. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. J Viral Hepat 2019;26:666-74. [PMID: 30740820 DOI: 10.1111/jvh.13075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
589 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
590 An C, Cheng Z, Yu X, Han Z, Liu F, Li X, Wu SS, Yu J, Liang P. Ultrasound-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: oncologic outcomes and advanced assistive technology. Int J Hyperthermia 2020;37:89-100. [PMID: 31969036 DOI: 10.1080/02656736.2019.1711203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
591 Fathi F, Sanei B, Ganjalikhani Hakemi M, Saidi RF, Rezaei A. Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:5593655. [PMID: 33987145 DOI: 10.1155/2021/5593655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 20.5] [Reference Citation Analysis]
593 Kang JH, Li MJ, Luan PP, Jiang DK, Chen YW, Xu X, Yu Q, Xu YW, Su Q, Peng WH, Jian WX. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation. Cell Biol Int 2020;44:2053-64. [PMID: 32584509 DOI: 10.1002/cbin.11414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66. [PMID: 28061016 DOI: 10.1111/liv.13357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
595 Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32:1975-1981. [PMID: 28295594 DOI: 10.1111/jgh.13783] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
596 An C, Li X, Yu X, Cheng Z, Han Z, Liu F, Yu J, Liang P. Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation. Cancer Biol Med. 2019;16:797-810. [PMID: 31908896 DOI: 10.20892/j.issn.2095-3941.2018.0486] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
597 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
598 Chong CCN, Lee KF, Chu CM, Chan AWH, Wong J, Chan SL, Lok HT, Fung AKY, Fong AKW, Cheung YS, Yu SCH, Johnson P, Lai PBS. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. HPB (Oxford). 2018;20:546-554. [PMID: 29352659 DOI: 10.1016/j.hpb.2017.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
599 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 2017;8:378-87. [PMID: 28261338 DOI: 10.7150/jca.16786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
600 Ding GY, Zhu XD, Ji Y, Shi GM, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Ann Transl Med 2020;8:204. [PMID: 32309351 DOI: 10.21037/atm.2020.01.44] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
601 Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL. Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation. Liver Transpl. 2018;24:1233-1242. [PMID: 29729113 DOI: 10.1002/lt.25194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
602 Zhou TH, Su JZ, Qin R, Chen X, Ju GD, Miao S. Prognostic and Predictive Value of a 15 Transcription Factors (TFs) Panel for Hepatocellular Carcinoma. Cancer Manag Res 2020;12:12349-61. [PMID: 33293862 DOI: 10.2147/CMAR.S279194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
603 Dai T, Peng L, Lin G, Li Y, Yao J, Deng Y, Li H, Wang G, Liu W, Yang Y, Chen G, Wang G. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol 2019;10:1049-63. [PMID: 31949922 DOI: 10.21037/jgo.2019.09.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
604 Kubo K, Kimura T, Aikata H, Takahashi S, Takeuchi Y, Takahashi I, Nishibuchi I, Murakami Y, Chayama K, Nagata Y. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma: Long-term outcome of SBRT for HCC. Hepatol Res 2018;48:701-7. [DOI: 10.1111/hepr.13063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
605 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
606 Yu J, Zhang Y, Zhou D, Wu J, Luo R. Higher expression of A-kinase anchoring-protein 1 predicts poor prognosis in human hepatocellular carcinoma. Oncol Lett 2018;16:131-6. [PMID: 29928393 DOI: 10.3892/ol.2018.8685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
607 He XX, Shi LL, Qiu MJ, Li QT, Wang MM, Xiong ZF, Yang SL. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochem Biophys Res Commun 2018;504:878-84. [PMID: 30219235 DOI: 10.1016/j.bbrc.2018.08.203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
608 Liu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D. Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics. Front Oncol 2020;10:539692. [PMID: 33072569 DOI: 10.3389/fonc.2020.539692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
609 Kim H, Ahn SW, Hong SK, Yoon KC, Kim H, Choi YR, Lee HW, Yi N, Lee K, Suh K. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. British Journal of Surgery 2017;104:1045-52. [DOI: 10.1002/bjs.10541] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
610 Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, Saracco GM. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scandinavian Journal of Gastroenterology 2018;53:734-40. [DOI: 10.1080/00365521.2018.1459824] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
611 Pinato DJ. Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma. Oncogene 2018;37:4635-8. [DOI: 10.1038/s41388-018-0262-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
612 Xu G, Zhu Y, Liu H, Liu Y, Zhang X. Long Non-Coding RNA KCNQ1OT1 Promotes Progression of Hepatocellular Carcinoma by miR-148a-3p/IGF1R Axis. Technol Cancer Res Treat 2020;19:1533033820980117. [PMID: 33349156 DOI: 10.1177/1533033820980117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
613 Lima LDP, Machado CJ, Rodrigues JBSR, Vasconcellos LS, Junior EP, Vidigal PVT, Resende V. Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:5970852. [PMID: 30112355 DOI: 10.1155/2018/5970852] [Reference Citation Analysis]
614 Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du X, Liu L. Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med 2020;8:539. [PMID: 32411762 DOI: 10.21037/atm.2020.02.85] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
615 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
616 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
617 Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci. 2017;62:3235-3242. [PMID: 28983724 DOI: 10.1007/s10620-017-4775-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
618 Ding Z, Lin K, Fu J, Huang Q, Fang G, Tang Y, You W, Lin Z, Lin Z, Pan X, Zeng Y. An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver. World J Surg Oncol 2021;19:181. [PMID: 34154624 DOI: 10.1186/s12957-021-02266-7] [Reference Citation Analysis]
619 Park HJ, Seo KI, Kim SJ, Lee SU, Yun BC, Han BH, Shin DH, Choi YI, Moon HH. Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Korean J Gastroenterol 2021;77:115-22. [PMID: 33658474 DOI: 10.4166/kjg.2020.148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol 2018; 10(9): 558-570 [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
621 Wang X, Qiao J, Wang R. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20203263. [PMID: 33111935 DOI: 10.1042/BSR20203263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
623 Sun J, Wu J, Liu C, Shi J, Wei Y, Zhou J, Zhang Z, Lau WY, Yan M, Cheng S. Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma. Cancer Biol Med 2021:j. [PMID: 34021538 DOI: 10.20892/j.issn.2095-3941.2020.0202] [Reference Citation Analysis]
624 Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, Shi Y, Xiao Y, Ding Z, Yang X, Tang M, Tang Z, Wang J, Lau WY, Fan J, Zhou J. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. Ann Surg. 2018;. [PMID: 29995681 DOI: 10.1097/sla.0000000000002942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
625 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
626 Bing Y, Tian M, Li G, Jiang B, Ma Z, Li L, Wang L, Wang H, Xiu D. Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients. Medicine (Baltimore) 2018;97:e12055. [PMID: 30170418 DOI: 10.1097/MD.0000000000012055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
627 Hirooka M, Hiraoka A, Ochi H, Kisaka Y, Joko K, Michitaka K, Hiasa Y. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. AJR Am J Roentgenol 2018;210:891-8. [PMID: 29412017 DOI: 10.2214/AJR.17.18177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
628 Wallace MC, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. Dig Dis Sci. 2017;62:2182-2192. [PMID: 28547649 DOI: 10.1007/s10620-017-4622-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
629 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
630 Long H, Zhong X, Su L, Huang T, Duan Y, Ke W, Xie X, Lin M. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34379248 DOI: 10.1245/s10434-021-10563-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
631 Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Maria Pellicelli A, Delle Fave G, Marignani M. Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. Annals of Hepatology 2017;16:107-14. [DOI: 10.5604/16652681.1226821] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
632 Kimura T, Aikata H, Doi Y, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Katsuta T, Kenjo M, Murakami Y, Awai K, Chayama K, Nagata Y. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies. Technol Cancer Res Treat. 2018;17:1533033818783450. [PMID: 29963972 DOI: 10.1177/1533033818783450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
633 Aref MH, Aboughaleb IH, Youssef AM, El-Sharkawy YH. Hyperspectral image-based analysis of thermal damage for ex-vivo bovine liver utilizing radiofrequency ablation. Surg Oncol 2021;38:101564. [PMID: 33865183 DOI: 10.1016/j.suronc.2021.101564] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
634 Lin PT, Teng W, Jeng WJ, Hsieh YC, Hung CF, Huang CH, Lui KW, Chen YC, Lin CC, Lin CY, Sheen IS, Lin SM. Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. Eur J Gastroenterol Hepatol 2020;32:1192-9. [PMID: 31851084 DOI: 10.1097/MEG.0000000000001637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Bai L, Ren Y, Cui T. Overexpression of CDCA5, KIF4A, TPX2, and FOXM1 Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development. J Comput Biol 2020;27:965-74. [PMID: 31593490 DOI: 10.1089/cmb.2019.0254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
636 Gong XQ, Tao YY, Wu YK, Liu N, Yu X, Wang R, Zheng J, Liu N, Huang XH, Li JD, Yang G, Wei XQ, Yang L, Zhang XM. Progress of MRI Radiomics in Hepatocellular Carcinoma. Front Oncol 2021;11:698373. [PMID: 34616673 DOI: 10.3389/fonc.2021.698373] [Reference Citation Analysis]
637 Reig M, Díaz-González Á, Bruix J. The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. Oncotarget 2017;8:106151-2. [PMID: 29290927 DOI: 10.18632/oncotarget.22382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
639 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 146] [Article Influence: 36.5] [Reference Citation Analysis]
640 Zhang XP, Wang K, Cheng SQ. Surveillance for Early-Stage Hepatocellular Carcinoma by Ultrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. Gastroenterology 2018;155:1274-5. [PMID: 30227109 DOI: 10.1053/j.gastro.2018.03.071] [Reference Citation Analysis]
641 Zhu J, Tang B, Gao Y, Xu S, Tu J, Wang Y, Yang W, Fang S, Weng Q, Zhao Z, Xu M, Yang Y, Chen M, Lu C, Ji J. Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. J Inflamm Res 2021;14:4089-109. [PMID: 34466015 DOI: 10.2147/JIR.S315957] [Reference Citation Analysis]
642 He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Med 2019;8:4200-13. [PMID: 31207163 DOI: 10.1002/cam4.2355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
643 Wang M, Gao Y, Feng H, Warner E, An M, Jia J, Chen S, Fang M, Ji J, Gu X, Gao C. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Cancer Med 2018;7:646-54. [PMID: 29473340 DOI: 10.1002/cam4.1341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
644 Ren L, Chen D, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer 2021;21:817. [PMID: 34266388 DOI: 10.1186/s12885-021-08565-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Ma XL, Zhu J, Wu J, Tian L, Gao YY, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett 2018;15:8396-404. [PMID: 29805574 DOI: 10.3892/ol.2018.8375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
647 Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. Biomed Res Int 2021;2021:5556306. [PMID: 33987439 DOI: 10.1155/2021/5556306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
648 Li B, Xu T, Liu C, Meng G, Sun Y, Qian L, Wang S, Wei J, Yu D, Ding Y. Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma. Sci Rep 2018;8:11197. [PMID: 30046116 DOI: 10.1038/s41598-018-29237-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
649 Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget 2018;9:16701-17. [PMID: 29682179 DOI: 10.18632/oncotarget.24673] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
650 Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol 2018;29:1061-7. [PMID: 29934260 DOI: 10.1016/j.jvir.2018.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
651 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
652 Sansone V, Le Grazie M, Roselli J, Polvani S, Galli A, Tovoli F, Tarocchi M. Telomerase reactivation is associated with hepatobiliary and pancreatic cancers. Hepatobiliary & Pancreatic Diseases International 2020;19:420-8. [DOI: 10.1016/j.hbpd.2020.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
653 Mai RY, Zeng J, Mo YS, Liang R, Lin Y, Wu SS, Piao XM, Gao X, Wu GB, Li LQ, Ye JZ. Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Ther Clin Risk Manag 2020;16:639-49. [PMID: 32764948 DOI: 10.2147/TCRM.S257218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Pan T, Mu LW, Wu C, Wu XQ, Xie QK, Li XS, Lyu N, Li SL, Deng HJ, Jiang ZB, Lin AH, Zhao M. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer. 2017;8:3506-3513. [PMID: 29151935 DOI: 10.7150/jca.19964] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
655 Rassam F, Olthof PB, Takkenberg BR, Beuers U, Klümpen HJ, Bennink RJ, van Lienden KP, Besselink MG, Busch OR, Verheij J, van Gulik TM. Scintigraphic liver function and transient elastography in the assessment of patients with resectable hepatocellular carcinoma. HPB (Oxford) 2019;21:626-35. [PMID: 30366883 DOI: 10.1016/j.hpb.2018.09.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
656 Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol 2020;235:9304-16. [PMID: 32330311 DOI: 10.1002/jcp.29730] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 33.0] [Reference Citation Analysis]
657 Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 2021;48:1604-17. [DOI: 10.1007/s00259-020-05095-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
658 Chen X, Zhang X, Li S, Zhang L, Zhang Q, Chen Z, Li L, Su Z, Cheng S, Wang C. Engineering of Yin Yang-like nanocarriers for varisized guest delivery and synergistic eradication of patient-derived hepatocellular carcinoma. Nanoscale Horiz 2019;4:1046-55. [DOI: 10.1039/c8nh00467f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
659 Chen J, Lai L, Lin Q, Huang W, Cai M, Zhu K, Huang M. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget 2017;8:408-17. [PMID: 27880724 DOI: 10.18632/oncotarget.13427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
660 Yokoo T, Singal AG, Diaz de Leon A, Ananthakrishnan L, Fetzer DT, Pedrosa I, Khatri G. Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. Abdom Radiol 2020;45:177-87. [DOI: 10.1007/s00261-019-02133-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
661 Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Mol Oncol. 2017;11:320-334. [PMID: 28164434 DOI: 10.1002/1878-0261.12039] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
662 Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577. [PMID: 28209963 DOI: 10.1038/srep42577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
663 Ji X, Zhou S, Yang P, Liu F, Li Y, Li H. Value of ultrasound combined with MRI in the diagnosis of primary and recurrent hepatocellular carcinoma. Oncol Lett 2019;18:6180-6. [PMID: 31788093 DOI: 10.3892/ol.2019.10945] [Reference Citation Analysis]
664 Zuo X, Kong W, Feng L, Zhang H, Meng X, Chen W. Elevated platelet distribution width predicts poor prognosis in hepatocellular carcinoma. Cancer Biomark 2019;24:307-13. [PMID: 30829614 DOI: 10.3233/CBM-182076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
665 Wang L, Zhang Z, Li Y, Wan Y, Xing B. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2480-505. [PMID: 33411682 DOI: 10.18632/aging.202281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
666 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
667 Lei Y, Gan H, Huang Y, Chen Y, Chen L, Shan A, Zhao H, Wu M, Li X, Ma Q, Wang J, Zhang E, Zhang J, Li Y, Xue F, Deng L. Digitoxin inhibits proliferation of multidrug-resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Oncol Lett 2020;20:71. [PMID: 32863904 DOI: 10.3892/ol.2020.11932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
668 Chai ZT, Zhang XP, Ao JY, Zhu XD, Wu MC, Lau WY, Sun HC, Cheng SQ. AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:650963. [PMID: 34123800 DOI: 10.3389/fonc.2021.650963] [Reference Citation Analysis]
669 Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (NY) 2021;46:2839-49. [PMID: 33388805 DOI: 10.1007/s00261-020-02884-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
670 Lou Y, Qiu W, Wu Z, Wang Q, Qiu Y, Zeng S. Mass spectral analysis of the multikinase inhibitor BZG and its metabolites and analysis of their binding to vascular endothelial growth factor receptor-2. Oncotarget 2017;8:29951-62. [PMID: 28415783 DOI: 10.18632/oncotarget.16264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
671 Zhu Z, Xu L, Zhuang L, Ning Z, Zhang C, Yan X, Lin J, Shen Y, Wang P, Meng Z. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma. Onco Targets Ther. 2018;11:6731-6740. [PMID: 30349306 DOI: 10.2147/ott.s173275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
672 Wang ZY, Chen QL, Sun LL, He SP, Luo XF, Huang LS, Huang JH, Xiong CM, Zhong C. Laparoscopic vs open major liver resection for hepatocellular carcinoma: systematic review and meta-analysis of comparative cohort studies. BMC Cancer. 2019;19:1047. [PMID: 31694596 DOI: 10.1186/s12885-019-6240-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
673 Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-2205. [PMID: 31358576 DOI: 10.1136/gutjnl-2019-318882] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 29.5] [Reference Citation Analysis]
674 Tanner B, Lu S, Zervoudakis G, Woodwyk A, Munene G. Coagulation profile following liver resection: Does liver cirrhosis affect thromboelastography? The American Journal of Surgery 2018;215:406-9. [DOI: 10.1016/j.amjsurg.2017.10.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
675 Zhang B, Chen M, Zhang Y, Chen W, Zhang L, Chen L. An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma. PLoS One 2018;13:e0196686. [PMID: 29718963 DOI: 10.1371/journal.pone.0196686] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
676 Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G, Felekouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol. 2018;44:195-208. [PMID: 29258719 DOI: 10.1016/j.ejso.2017.11.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
677 Wang TC, An TZ, Li JX, Pang PF. Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE. Risk Manag Healthc Policy 2021;14:2589-600. [PMID: 34188570 DOI: 10.2147/RMHP.S316740] [Reference Citation Analysis]
678 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
679 Lin Z, Miao D, Xu Q, Wang X, Yu F. A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:10724-48. [PMID: 33850056 DOI: 10.18632/aging.202871] [Reference Citation Analysis]
680 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
681 Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33:347-354. [PMID: 28589639 DOI: 10.1111/jgh.13843] [Cited by in Crossref: 54] [Cited by in F6Publishing: 64] [Article Influence: 18.0] [Reference Citation Analysis]
682 Zhang L, Wang Z, Li M, Sun P, Bai T, Wang W, Bai H, Gou J, Wang Z. HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells. Front Cell Dev Biol 2021;9:707073. [PMID: 34527669 DOI: 10.3389/fcell.2021.707073] [Reference Citation Analysis]
683 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
684 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
685 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: